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ABSTRACT
Aims: Carotid atherosclerotic disease is a major cause of stroke, but it may remain clinically 
asymptomatic. The factors that turn the asymptomatic plaque into a symptomatic one are not 
fully understood, neither are the subtle effects that a high-grade carotid stenosis may have on 
the brain. The purpose of this study was to evaluate brain microcirculation, diffusion, and 
cognitive performance in patients with a high-grade stenosis in carotid artery, clinically either 
symptomatic or asymptomatic, undergoing carotid endarterectomy (CEA). We wanted to find 
out whether the stenoses are associated with diffusion or perfusion abnormalities of the brain 
(I, II) or variation in the cognitive functioning of the patients (III), and to what extent the 
potential findings are affected by surgery. We further aimed to compare the findings of the 
clinically symptomatic and asymptomatic subjects (I-IV). Microcirculation was studied both 
from the viewpoint of perfusion imaging (II) and the procoagulant and anticoagulant activities 
in the blood (IV). Coagulation and fibrinolytic parameters were compared with the rate 
microembolic signals (MES) and the macroscopic appearance of stenosing plaques in surgery 
(IV). 
 
Methods: We recruited 92 consecutive consenting patients fulfilling strict inclusion criteria 
who were referred to CEA to Helsinki University Central Hospital, ending up with 98 
endarterectomies, 54 on symptomatic and 44 on asymptomatic carotids. We used the total 
study population in study IV, collecting blood samples prior to operation for determination of 
fibrinogen, thrombin-antithrombin complex, prothrombin fragments PF 1 and 2, tPA antigen 
and activity, plasminogen activator inhibitor 1 (PAI-1) antigen and activity, D-dimer, and 
hematocrit. The patients underwent transcranial Doppler (TCD) monitoring of MES counts 
and vasoreactivity testing with determination of breath-holding index (BHI) before and after 
surgery (II, IV). During the standard CEA, the macroscopic characteristics of the exposed 
plaque were recorded. A subpopulation of 46 subjects underwent magnetic resonance imaging 
with diffusion-weighted and perfusion-weighted sequences with dynamic susceptibility-
weighted bolus tracking approach on the day before CEA, as well as 3 and 100 days 
afterwards (I-III). Of the MR-imaged patients, 44 underwent a comprehensive domainwise 
neuropsychological assessment according to the same schedule (III). The severity of white 
matter lesions was graded from conventional images. The imaging and neuropsychological 
parameters were compared using data on matched, strictly healthy control populations (I, III).     
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Results: At baseline, regardless of symptoms, the average apparent diffusion coefficients 
were higher in the ipsilateral white matter (WM), and they were higher than in control 
subjects. After CEA, the interhemispheric difference was abolished, but the levels remained 
higher than in controls (I).  
 
Patients with symptomatic stenoses had longer mean transit times and lower cerebral blood 
flow at baseline than asymptomatic patients, and the difference was more pronounced in WM. 
Perfusion deficits were associated with symptomatic status, and they were corrected by CEA. 
In TCD, preoperative pulsatility was lower in symptomatic patients, and only their 
vasoreactivity improved after surgery (II).   
 
The baseline cognitive performance of the patients was poorer than that of healthy controls in 
all domains. It was inversely correlated to the severity of leukoaraiosis. Despite transient 
cognitive worsening after surgery, mostly in attentional tasks, the cognitive performance of 
the patients improved similarly than in control persons over the months of study. However, 
patients with deepest hypoperfusion displayed a greater cognitive improvement, most clearly 
in the domain of executive functions. 
 
Patients with symptomatic plaques had higher hematocrit and a trend for higher tPA antigen 
and MES rate. Hematocrit, tPA antigen, PAI-1 antigen and activity correlated with the degree 
of stenosis. In multivariate analysis, tPA antigen and high hematocrit were risk factors for 
symptomatic stenosis.   
 
Conclusions: Carotid stenosis has an effect on diffusion in the ipsilateral WM, and the effect 
is partially reversible by CEA. The finding may be associated with the development of 
leukoaraiosis (I). Asymptomatic and symptomatic subpopulations differ from each other in 
terms of microcirculation and in their vascular physiological response to removal of stenosis 
(II). Although CEA may be associated with a transient cognitive decline, a true improvement 
of cognitive performance by CEA is possible in patients with the most pronounced perfusion 
deficits (III). Mediators of fibrinolysis and unfavourable hemorheology may contribute to the 
development of a symptomatic disease in patients with a high-grade stenosis (IV).  
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1. INTRODUCTION 
 
Carotid arteries are the major suppliers of the human cerebral circulation. They are also 
predilection sites for atherosclerotic change, a long-standing inflammatory process of the 
arteries which is the most formidable threat to well-being in aging individuals in the Western 
world 1, 2. One of the central manifestations of atherosclerosis is stroke, resulting in the 
greatest loss of quality-adjusted life years of all diseases 3.  In Finland, approximately 14 000 
cases of stroke occur every year 4.  Carotid occlusive disease accounts approximately for 15-
20 % of all strokes 5. A high-grade carotid stenosis (CS), being one of the major causes of 
stroke, is an important target for preventive treatment.   
 
Stenosing atherosclerotic lesion of the carotid artery may cause stroke by giving rise to 
embolization of thrombi or plaque debris in the brain or by impairing brain perfusion 6, 7. The 
development of CS or occlusion may also occur silently without recognized neurological 
symptoms. Surgical treatment of a high-grade stenosis by carotid endarterectomy (CEA) is an 
evidence-based form of treatment, and it improves the long-term outcome and survival of 
patients with a symptomatic carotid stenosis, but in asymptomatic carotid stenoses the benefit 
is considerably smaller 8, 9.  Intensive research has suggested many potential biological 
markers and pathological changes that may render a plaque more vulnerable, but still the 
process of transformation into an unstable plaque is incompletely understood 10-12. 
 
The role of impaired microcirculation in producing cerebral symptoms is less clear. 
Unfavourable anatomy or physiology in form of a less well-developed collateralization or 
cerebrovascular reactivity may give rise to symptoms in a susceptible individual, and the 
rheological properties of blood could also have an effect, as well as the balance between 
procoagulant and anticoagulant factors in the blood.  It has been suggested that a tight CS 
might contribute to the development of degenerative changes in the white matter, often 
referred to as leukoaraiosis (LA) or white matter lesions (WML), consisting of patchy or 
diffuse areas of hypodensity in the cerebral white matter (WM) on computed tomography  or 
white-matter hyperintensities (WMH) on magnetic resonance imaging (MRI) 13, 14. The 
association between CS and LA has not been conclusively shown, although hypoperfusion is 
considered to play a key role in the pathogenesis of LA 13, 14. 
 
Does CEA have other effects on the brain tissue apart from the prophylaxis of cerebrovascular 
events? Since the advent of this treatment, the possibility of improving cognitive functioning 
by restoring blood flow has been discussed. Despite a number of studies, there is no 
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conclusive evidence that any improvement would occur 15. To the contrary, surgery may 
expectedly be a risk factor causing at least a transient decline of cognitive functions even in 
absence of clinical stroke 16-18. Many of the studies are descriptive, and repeated assessment 
of cognition is challenging in patients with multiple concomitant diseases and other 
confounding elements. 
 
The present-day MRI methodology provides new tools for brain imaging. With diffusion-
weighting (DWI) it is possible to reveal hyperacute ischemic change and have an in-vivo 
measure of biological diffusion shedding new light e.g. to the pathophysiology of WM 19-21.  
Perfusion-weighted imaging (PWI) gives a rapid assessment of cerebral microcirculation: 
dynamic susceptibility-contrast  MRI (DSC MRI) is a widely-used method utilizing a 
simultaneous collection of the MR signal during the passage of a paramagnetic contrast agent 
bolus through the brain 22, 23. By acquisition of data it is possible to determine perfusion using 
mean transit time of the bolus (MTT) , cerebral blood volume (CBV), and cerebral blood flow 
(CBF) 24-27. 
 
Elucidation of the microcirculation and diffusion by the new MRI techniques could provide 
new insight into the effect of a high-grade stenosing lesion of carotid artery and its surgical 
removal on the subserved brain vasculature, in addition to the traditional methods of 
neuropsychological assessment and the transcranial Doppler ultrasonology.  Combining an 
assay of the central elements of coagulation, fibrinolysis, and hemorheology would integrate 
the approach with the key determinants of microcirculation on the blood level.  
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2. REVIEW OF THE LITERATURE 
 
2.1 Anatomy and physiology of carotid arteries and the cerebral circulation   
 
The brain is one of the most metabolically active organs, reflected by a high rate of oxygen 
consumption 28. As the brain is unable to store energy, the neurons are most dependent on 
adequate continuous delivery of oxygen, and blood supply to the brain is highly prioritized in 
the circulatory system. Although the brain represents only approximately 2 % of the body 
mass its share of the resting cardiac output is one-fifth 29. In cases of circulatory compromise 
this share may considerably increase at the cost of other end-organs. Intracranially, the blood 
flow is protected by vascular anatomy providing collateral circulation, and by autoregulation 
of cerebral blood flow (CBF).     
 
2.1.1  Cerebral arterial circulation 
 
The brain receives its blood supply principally through four arteries: two internal carotid 
arteries (ICA) and two vertebral arteries (VA) [Figure 1]. Convexity of the aortic arch gives 
rise to the brachiocephalic trunk (innominate artery) giving origin to the right common carotid 
artery (CCA) and the right subclavian artery.  The left common carotid and the left subclavian 
arteries originate directly from the aortic arch. At the level of the upper border of the thyroid 
cartilage, the CCAs bifurcate into external and internal carotid arteries (ECA, ICA), the 
former supplying the jaw, face, neck, and meninges, and the latter passes up the neck without 
branching, enters the skull through the carotid canal of the petrous bone and supplies the 
anterior circulation of the brain as well as the eye. Within the cranium, ICA forms a sigmoid 
carotid siphon which emits the ophthalmic artery before piercing through dura and passes 
medially to the anterior clinoid process, ascending to the bifurcation where it gives rise to the 
anterior and middle cerebral arteries (ACA, MCA) right after the origin of the posterior 
communicating artery. MCA supplies the convexity of the hemisphere and ACA 
approximately the anterior and upper half of the medial aspect of the hemisphere. The ACAs 
are interconnected by anterior communicating artery (ACoA) in front of the optic chiasm. 
Vertebral arteries arise from the proximal subclavian artery, ascending through the foramina 
of the transverse processes of the cervical vertebrae. They pass posteriorly around the 
articular processes of the atlas, entering the skull through the foramen magnum. The two 
vertebral arteries join each other at the pontomedullary junction, forming the basilar artery 
(BA) in the midline. BA ascends ventrally up to the ponto-mesencephalic junction, dividing 
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into the posterior cerebral arteries (PCA). BA gives rise to anterior inferior cerebellar and 
superior cerebellar arteries along with numerous paramedian, short and long circumferential 
penetrators. PCAs encircle the midbrain at the tentorial level, and they supply the occipital 
lobe and the inferior part of the temporal lobe. Small perforating arteries arising from PCA 
supply also the midbrain, the thalamus, hypothalamus and geniculate bodies. The posterior 
communicating arteries (PCoA) anastomose with the PCAs after their origin. There are many 
anatomical variations to the basic arterial tree structure.  
Carotid arteries and their branches (the anterior circulation) provide approximately three 
fourths of the total inflow to the brain in humans, the rest entering the skull through the 
vertebrobasilar system (the posterior circulation) to the posterior parts of the brain. The 
systems anastomose at the base of the brain to form the circle of Willis, where PCoAs 
interconnect MCA and PCA, and so the most cranial part of ICA is connected with the 
proximal PCA. The carotid flow normally subserves predominantly the ipsilateral cerebral 
circulation with little cross-over flow to the contralateral side 29. 
 
Collateralization 
 
When ICA fails to produce the ordinary supply to the cerebral vasculature, mainly five 
sources of alternative flow may be recruited. They are commonly divided into primary and 
secondary collaterals. The primary collaterals are arterial segments of the circle of Willis, 
providing existing anastomoses for immediate diversion of blood to areas with shortage of 
flow. The most important primary collateral route in ICA stenosis or occlusion is the opposite 
ICA providing the flow via the circle of Willis through ACA. Reversal of flow in the 
ophthalmic artery is a sign of a secondary collateralization and exchange of blood from ECA 
to ICA, and another secondary source is leptomeningeal anastomoses on the brain surface. 
Adequate collateralization may prevent haemodynamic insufficiency and protect from strokes 
30-34; on the other hand, presence of leptomeningeal collaterals has been associated with a 
greater stroke risk in a few studies 35, 36. Even in cases of well-developed collateral supply 
there are regions of the brain that are especially vulnerable to perfusion deficit: borderzone 
areas between basal cerebral arterial territories including the internal borderzone in the 
centrum semiovale and corona radiata, as well as the areas subserved by perforating end-
arteries supplying the WM and subcortical GM nuclei. There is considerable individual 
variation in the boundary zones 37. 
 
Secondary collaterals may represent anatomically existent routes, but enhanced capacity of 
these pathways may require time to develop. The opening and recruitment of collaterals may 
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be mediated by haemodynamic, metabolic, and neural mechanisms, and angiogenesis may 
stimulate their growth. There are also precapillary anastomoses between arterioles, but their 
clinical significance in case of an impending infarction is inconsiderable 29.  
 
The determination of collateral recruitment is not customary in the conventional radiological 
work-up, and the evaluations have appeared inconsistent even in the digital subtraction 
angiography (DSA) that provides best information invasively. The modern methods of 
imaging corroborate the importance of the variable collateral anatomies for CBF 31, 38. 
However, the contribution of an individual pathway is not easily assessed or quantified in the 
clinical practice. Obviously, a more refined diagnostic methodology and approach to study 
collateralization is needed. 
 
 
 
Figure 1. Blood supply to the brain.  
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Figure 2. The supply territories of the main cerebral arteries, middle cerebral (MCA), anterior 
cerebral (ACA), and posterior cerebral (PCA) arterial territory.  
 
 
 
2.1.2  Cerebral perfusion and its physiology 
 
Cerebral perfusion denotes microcirculation of the brain, which essentially refers to the blood 
flow through the cerebral vascular bed with its capillary networks, and the exchange of gases 
and nutrients therein. Most of the blood in the brain is located in the capillaries, and this 
volume forms approximately 4 % of the GM and 1-2 % of the WM volume. The net blood 
pressure causing the flow through the capillary network is called cerebral perfusion pressure 
(CPP), and it represents the pressure gradient across the cerebral vascular bed. Consequently, 
for an estimate of mean CPP, intracranial pressure is subtracted from the mean arterial 
pressure 39. CPP needs to be maintained within adequate limits to avoid hypoperfusion 
leading to ischaemia, as well as hyperperfusion implying inadequately high perfusion pressure 
and blood flow, which can be detrimental to the brain tissue and lead to hyperemia, vasogenic 
oedema, and secondary elevation of the intracranial pressure 39. 
 
The efficiency of microcirculation is dependent on arterial blood pressure, blood velocity, the 
structure and characteristics of the capillary network and its permeability, and the diffusion 
rates of gases and solutes. Usually, the perfusion is symmetrical in the hemispheres, and the 
perfusion rates are higher in the GM than in the WM. In resting humans, the average blood 
flow in GM is estimated to be 69 ml/100 g/min, and in WM 28 ml/100 g/min.  Brain 
perfusion may be characterized with parameters such as mean transit time (MTT) in seconds, 
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cerebral blood volume (CBV) in mL/100 g, and cerebral blood flow (CBF) in mL/100 g/min, 
and their relationship may be given as 
   
                          MTT = CBV / CBF                    25, 26, 39-41 
 
CBF is influenced by many factors including carbon dioxide, oxygen, blood pressure, and 
metabolic demand. Its coupling to brain metabolism is tight, and the local blood flow varies 
markedly in proportion to brain activity as proposed originally by Roy and Sherrington in 
1890 42, to ensure adequate oxygen delivery. How much the oxidative metabolism increases 
with brain activation and what mechanisms mediate the haemodynamic response are still 
debated issues, although it is evident that glial cells and calcium also play a role in the 
signaling process of neurons 43, 44. An important regulator of basal CBF is nitric oxide 
synthesized by endothelial cells, catalyzed by one of the isoforms of nitric oxide synthetase  
(eNOS) 45-47. 
 
Cerebrovascular reactivity 
 
Cerebrovascular autoregulation refers to the fast-acting metabolic, myogenic, and neurogenic 
mechanisms that maintain cerebral blood flow constant over a wide range of perfusion 
pressure, shielding the brain against hypoxia at low perfusion pressure and against brain 
oedema at high perfusion pressure 48-50.  
 
This constancy is mainly brought on by vasodilatation or vasoconstriction on the precapillary 
level depending on whether perfusion pressure needs to be increased or decreased. Although 
changes in blood pressure are transmitted to the cerebral circulation, normally functioning 
autoregulation tends to return the original level within seconds 49.  The overall mechanism of 
autoregulation is not fully understood. The myogenic hypothesis indicating a direct response 
of smooth muscle in resistance arterioles to alterations in perfusion pressure could explain the 
short reaction time. Endothelial factors, primarily nitric oxide, have been attributed a tentative 
mediating role in autoregulatory response; however, despite a small pilot study finding 
impaired dynamic autoregulation after nitric oxide synthetase inhibition in humans, the 
experimental results are mixed 51. 
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Figure 3. Blood pressure – cerebral blood flow curve showing the autoregulatory plateau 
(reproduced with permission from Hademenos GJ, Massoud TF. The Physics of Cerebrovascular Diseases. New 
York: Springer-Verlag; 1998) 
 
 
The efficiency of autoregulation as a physiological mechanism is restricted by internal 
thresholds; in the normal brain, CBF is maintained constant at arterial pressures 
approximately over the range from 50-65 to 125-170 mmHg according to various estimates 29, 
49, 52. Yet, the upper and lower ends of the autoregulatory plateau are not constant. Many 
external factors have a strong bearing on the autoregulatory function: autoregulation is 
strongly influenced by arterial carbon dioxide and oxygen levels, e.g. attenuated by 
hypercapnia and enhanced by hypocapnia, largely mediated by pH changes, and sympathetic 
activation shifts the autoregulatory curve rightwards preventing exercise from leading into 
cerebral hyperperfusion 49, 53. Sex steroid hormones have been shown to change vascular 
reactivity, estrogen tending to enhance vasodilation and testosterone vasoconstriction 54-57. 
Age and gender are determinants of cerebral vasoreactivity as well 58-60. Long-standing 
changes may be induced by chronic states, such as chronic hypertension causing a rightward 
shift in the autoregulatory curve 61. 
 
Vasomotor reactivity implies the compensatory potential of the blood-flow regulating vessels, 
primarily arterioles and precapillary sphincters with diameters not more than 50 m by 
change of their diameter. This potential can be specifically tested by observing the response in 
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CBF or blood flow velocity to an evoked haemodynamic change, e.g. in arterial blood 
pressure or posture, or to a change in the carbon dioxide content of blood, which may be 
induced with CO2 inhalation, breath holding, hyperventilation, or administration of 
acetazolamide, carbonic anhydrase, which has a potent vasodilating effect on the cerebral 
resistance vasculature 48, 62, 63. Also changes in oxygen content trigger autoregulatory 
responses. Vasoactive infusions have also been used, such as L-arginine. Continuous 
assessment methods utilizing spontaneous variations in CPP without specific clinical 
intervention have also been described 64, 65. According to the testing methodology we can talk 
either about static or dynamic autoregulation: the former refers to an overall comparison of 
steady-state measurements whereas the latter takes into account the latency of the response 66, 
67. 
 
Autoregulation is impaired by several diseases such as ischemic stroke, traumatic brain injury, 
and subarachnoid haemorrhage 68-71. Autoregulatory reactions may gradually decline in 
increasing degrees of ischaemia, and clinically lower vasomotor reactivity has been detected 
ipsilaterally in symptomatic carotid stenosis 72, 73. Impaired vasomotor reactivity has been 
associated not only with poorer collateralization  but also with a greater stroke risk in ICA 
stenosis or occlusion and the perioperative need for shunting during CEA 34, 74-78. Conversely, 
the significance of autoregulation as a protective mechanism is evident in traumatic brain 
injury, in which preserved autoregulation is associated with good outcome 64, 65, 68.  
 
 
2.2  Imaging methods of carotid disease and cerebral blood flow 
 
Cerebral angiography became the study of choice for brain vasculature and disorders after its 
invention 1927, and it gave the user a dynamic qualitative image of the cerebral circulation as 
filling-up and then wash-out of vessels with contrast. Later on, the revolutions of computed 
tomography (CT) and magnetic resonance imaging (MRI) for structural imaging restricted the 
use of cerebral angiography to vessel imaging. At present, digital subtraction angiography 
(DSA) is still considered the gold standard for the imaging of a carotid stenosis as well as 
cerebral vasculature. However, in consequence of the fast technical development CT 
angiography and MR angiography together with ultrasound, even in vessel imaging DSA has 
to a great extent been replaced by less invasive or non-invasive methods in the clinical 
practice, and the safer newer methods have also paved the way for quantitative assessment of 
CBF. 
 
  
 
 
 
 
A = narrowest point of ICA stenosis 
B = normal-width artery distal to ICA stenosis 
C = estimated original width at the narrowest     
       point of stenosis    
D = normal CCA proximal to the bulb 
 
 NASCET method of measurement: 
stenosis = (B-A)/B  100 %.  
 ECST method:  
       stenosis  = (C-A)/C  100 %.  
 Common carotid method:  
       stenosis  = (D-A)/D  100 %
Figure 4. Calculation of stenosis degree.  
2.2.1  Measurement of carotid stenosis 
Subjective visual assessment of the stenosing lesion is not sufficient for guiding treatment 
decisions but a method of measurement is necessary 79. A variety of methods have been used 
to this end, which together with the generally poor study designs has largely undermined the 
possibility of meta-analytical approach 80. Of three most commonly used methods, the 
NASCET (The North American Symptomatic Carotid Endarterectomy Trial) measurement 
has become the standard in practice 81, 82. The NASCET method compares the minimal 
residual lumen at the point of stenosis to a normal ICA width, with parallelly aligned walls, 
measured beyond the bulb area (Figure 4) 81. The ECST (European Carotid Surgery Trial) 
measurement compares the minimal residual lumen at the point of stenosis to the estimated 
‘normal’ diameter of the carotid bulb 83. The common carotid index method comparing the 
minimal residual lumen to the diameter of normal CCA may be the most reproducible but 
despite an earlier recommendation it is not commonly used 84. The ECST method involves a 
hypothetical measurement that may induce subjective variation, and it leads to higher 
percentages of stenosis compared to NASCET method, which could produce an 
underestimation of percentage and cannot be applied in cases of near-occlusion. In principle, 
the three measurements are mathematically convertible 84.  The percentages of stenosis in the 
following are given according to NASCET method if not otherwise indicated. 
 
  
   
  
   
  
 
21  
2.2.2  Imaging cerebral blood flow 
 
The first successful quantitative measurements of the CBF with inhaled nitrous oxide as the 
tracer were published in 1945 85. At present, there are several techniques for imaging and 
quantitative measurement of CBF and metabolism in addition to structural imaging. Part of 
them utilize different kinds of diffusible inert tracers, nonradioactive such as 131Xenon in 
xenon-enhanced CT, or radioactive such as technetium-99m-hexamethyl-propylamine-oxime 
(99Tc-HM-PaO) in single-photon emission computed tomography (SPECT) or various 
positron-emitting radioisotopes, e.g. 18-fluorodeoxyglucose (18FDG) or 15-oxygen (15O) in 
positron emission tomography (PET).  These methods are based on quantification of the 
accumulated diffusible indicator in the brain tissue, and consequently they give an image of 
the true perfusion of the tissue. The advantages of xenon-enhanced CT are acquisition of both 
structural images and quantitative CBF estimates, whereas the disadvantages are the sedative 
and CBF-increasing effect of the tracer as well as often movement artifacts and low signal-to-
noise ratio 86. PET is a versatile tool yielding several physiological parameters in addition to 
flow, such as oxygen metabolism, but it is better suited to research purposes as its use is 
restricted by availability, technical demands, expenses, and the limited spatial resolution. 
Implementation of single-photon emission computed tomography is simpler and the expenses 
are more reasonable but its resolution is lower and quantitation problematic, and the longer 
half-lives of the radiotracers make repeated measurements difficult. 
 
The tracers may also be intravascular, measuring the flow inside the vascular compartment, as 
in perfusion CT and dynamic susceptibility-contrast perfusion MRI (DSC MRI). The high-
speed helical CT scanners and image reconstruction software have enabled the development 
of perfusion CT methodology, where the acquisition of data is possible during the passage of 
an iodinated contrast agent, and the perfusion can be calculated on a pixel-by-pixel basis from 
the arterial enhancement (arterial input function). The advantages of the method are 
acquisition of both structural images, angiography, and maps of mean transit time (MTT) and 
cerebral blood volume (CBV) and CBF, on a widely available equipment. The disadvantages 
are the burden of radiation and contrast agent exposure, which limit repeated imaging. Up to 
now, the coverage of the brain has also been limited, but this setback is greatly overcome by 
the modern multi-detector row scanners. At present, perfusion CT has already become a 
validated and fast technique that can be used to guide acute stroke therapy and predict 
outcome. In a similar manner, DSC MRI utilizes a nondiffusible intravascular tracer whose 
effect on magnetic susceptibility during its passage is evaluated by a fast series of MR 
scanning (the MRI methodology is discussed in more detail in the section 2.2.4) 
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2.2.3  Ultrasonology 
                                                          
Medical ultrasound (US) utilizes emission of high-frequency inaudible sound pulses (usually 
of the range 2-20 MHz) and gathering of the reflected sound from the body. The pulses are 
repeated in a rapid succession in slightly different directions, and the position of the structure 
producing the reflection can be calculated from the time interval between transmission of the 
pulse and reception of the reflection. It is an ideal method for soft tissue imaging, limited by 
its inability to penetrate air or gas. Speed of ultrasound varies in different tissues depending 
on their density and elasticity; for instance, bone distorts and rapidly attenuates the 
propagation of the sound wave.  
 
An observer of a moving source of sound waves will measure higher or lower frequency than 
that actually emitted by the source depending on whether the source is moving towards or 
away from the observer. This phenomenon is known as the Doppler effect, named after the 
Austrian physicist Christian Doppler who first described it. The Doppler shift, frequency 
difference between the emitted and reflected sound signal, can be utilized in medical 
ultrasonology of moving targets by transmitting a sound signal and observing the change of 
frequency. The frequency difference can be given as 
 
  fd =  ft  -  fr = 2 ft v cos  /c 
 
where v is the velocity of the target, c the speed of sound in tissue,  the angle between the US 
beam and the moving target, and  ft  the transmitted and  fr the received frequency.  
 
In vasculature, the reflection is predominantly from moving erythrocytes in the sample 
volume, and thus the Doppler shift signal contains a spectrum of frequencies. The ultrasound 
system may utilize continuous wave emission with a separate transducer for reception of the 
returning ultrasound, or pulsed wave emission which can provide also a depth estimation of 
the source of the reflected beam with a single transducer both emitting and receiving the 
sound 87. With application of different ultrasonological techniques it is possible to visualize 
the vessel morphology (B-mode imaging), combine the spectral analysis or colour-coded 
blood flow with morphology in a real-time viewing (Duplex sonography or colour-coded 
Doppler flow imaging). Power Doppler imaging produces colour coding of the flow based on 
the amplitude of the signal. With modern techniques, it has been possible to improve the 
detection of surface morphology with construction of three-dimensional ultrasound or 
enhance the signal-to-noise ratio with contrast agent and harmonic imaging 88. 
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Noninvasive imaging is the mainstay of screening methodology in vascular disease. Since the 
introduction of the Doppler principle into the medical field over three decades ago, US 
methods have become the first line of imaging. In investigation of carotid disease, US is the 
most commonly performed imaging method 89. In principle, US examinations are easily 
applied, but they require training and expertise, and as such they are highly operator-
dependent. They can be used repeatedly, and the cost is very reasonable in comparison to 
other techniques. Transcranial Doppler approach was introduced into clinical practice in 1981 
90.   
 
Ultrasonological determination of stenosis degree is the screening method for detection of 
carotid stenosis. In its early forms, the atherosclerotic process may be reflected by the 
measured thickness of the wall structure  (intima-media thickness, IMT), which  has been 
used as a surrogate in many follow-up trials and is associated with clinical atherosclerosis, 
e.g. coronary events 91.  In intermediate and high-grade stenosis of advanced atherosclerotic 
process, it is possible to observe the echogenicity of the plaque. Fibrous tissue and 
calcifications produce more shadowing, and lipid-laden plaques are associated with more 
echolucency, as well as intraplaque haemorrhage or thrombosis. Heterogeneous plaques and 
echolucency as a sign of greater lipid content or intraplaque haemorrhage have been 
associated with a greater stroke risk 92; however, the viewing angles are limited, and the 
assessment of plaque morphology or surface structure is not considered very reliable 93, 94. So 
far, studies on the predictive value of intraplaque composition have not yielded uniform 
results that would guide treatment decisions. Finally, at the later stages of atherosclerotic 
process, detection of the stenosis and quantification of its degree is the most clinically 
important parameter. Consequently, different diagnostic criteria have been proposed for a 
high-grade (70-99 %) stenosis. Peak systolic velocity (PSV) > 230 cm/sec, end-diastolic 
velocity (EDV) > 100 cm/sec, and ICA PSV/CCA PSV ratio > 4.0 have been found to provide 
optimized accuracy, and these cut-off points form the basis of a consensus statement for the 
US velocity criteria in CS 89. However, these criteria do not apply to near-occlusions, and US 
cannot reliably differentiate occlusion from a near-total carotid occlusion 88, 89. 
 
Transcranial Doppler ultrasound 
 
Transcranial Doppler ultrasound (TCD) measures local blood flow velocity and direction in 
the proximal intracranial arteries through skull bone or its natural openings 90.  It is mainly 
used in the assessment and management of cerebrovascular disease, such as acute infarction, 
emergence of vasospasm after subarachnoid haemorrhage or elevations of intracranial 
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pressure. It is a suitable method for continuous monitoring, and it can be used to demonstrate 
right-to-left cardiac shunts, to quantify the rate of microembolization to the brain, to support 
the diagnosis of cerebral circulatory arrest, or to study vasomotor reactivity 95. Recent studies 
indicate that TCD may enhance the lysis of acute cerebrovascular thrombi, because the 
recanalization rate in TCD-monitored rtPA-thrombolyses has been higher; however, proper 
application may be crucial as the insonation may not be harmless 96-98. 
 
The major advantages are low cost of use, noninvasiveness, repeatability, option of 
continuous monitoring, and that it provides the simplest bedside method for non-invasive 
crude estimation of CBF. In addition to being operator-dependent, the main disadvantage is 
limitation to imaging of certain segments of the main intracranial arteries, and a minority of 
subjects do not have any applicable US window at all temporally 95. A more accurate 
depiction of vascular anatomy and smaller arterial branches and venous structure is possible 
with transcranial colour-coded sonography methodology. 
 
Pulsatility index 
 
Gosling index of pulsatility (PI) is a measure for the shape of the spectral waveform, 
calculated by 
 
  PI = (Peak systolic velocity – end-diastolic velocity)/mean flow velocity   99 
 
PI is a relatively constant TCD parameter, normally within the range of 0.5-1.4  100. Higher 
values are associated with decreased compliance of the vasculature or increased intracranial 
pressure, lower values with low-resistance states such as poststenotic flow or arteriovenous 
malformation 100. Although PI is often considered a measure of downstream vascular 
resistance, it is dependent on the driving force as well as downstream impedances, so it is an 
inaccurate reflection of the vascular resistance 101.   
 
Detection of emboli 
 
Particulate and gaseous material in the blood flow differ from erythrocytes by acoustic 
impedance properties; the reflection and the scattering of the Doppler US beam enhances the 
intensity of the received signal which is called ‘a high-intensity transient’ signal (HIT), or 
generally microembolic signal (MES) in TCD. These have been detected in various 
manifestations of vascular and cardiac disease, such as carotid stenosis, aortic arch atheroma, 
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atrial fibrillation, or myocardial infarction, or general cerebrovascular disease. Especially, 
HITS may be encountered in connection with cardiovascular procedures and surgery, 
including coronary bypass, catheterization and cardioversion, as well as carotid 
endarterectomy or angioplasty. Therefore, continuous monitoring of MES can be used in 
surveillance under operation. The problems of MES detection are not only the variability of 
occurrence but also of the methodology and detection thresholds, determination of the type of 
the signal detected, and the differentiation from artifacts, and these reduce the interobserver 
agreement and overall comparability of studies. New automated methods of discrimination 
are being developed. 
 
In carotid occlusive disease, ulceration of the plaque with platelet aggregates and fibrin clots 
may give rise to MES, and asymptomatic occurrence of MES has indicated an increased risk 
of cerebral ischemic events 102. It is suggested that MES detection could also be used in 
evaluation of response to antithrombotic therapy 103-105. During CEA, TCD monitoring may 
provide data on the MES occurrence in different phases of the procedure as well as yield real-
time haemodynamic information. MES maxima usually occur during the dissection phase, 
shunting, release of clamping, closure of wound, and during the first hours after the 
procedure.  Their number has correlated to the ensuing MRI lesions, and the development of 
postoperative cerebral ischaemia 106, 107. The haemodynamic monitoring may reveal decreases 
in flow velocities that indicate corrective measures to be taken, e.g. shunt placement, or 
appropriate medication and fluid administration. In one study, MES during dissection and 
closure, > 90% decrease in MCA velocity and > 100% increase in PI at clamp release were 
associated with intraoperative stroke 108. Correspondingly, a notable (> 100%) rise in flow 
velocity after clamp release may predict increased risk for postoperative hyperperfusion 
syndrome 109, 110. 
 
Cerebrovascular vasomotor reactivity 
 
Since the vasodilating effect of carbon dioxide (CO2) is primarily based on vasoreactivity of 
arterioles and precapillary sphincters, the blood velocity in the basal arteries is roughly 
proportional to CBF. As the effect on the basal cerebral arteries is small, TCD is a suitable 
and widely adopted method for evaluation of reactivity of the brain vasculature 63, 111, 112. 
Thus, on manipulation of  pCO2  concentration, the change in flow velocity in basal arteries 
reflects the change of diameter in vasomotor arterioles.  A simple screening test for co-
operative subjects is breath-holding, where the patient is instructed to hold the breath for at 
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least 30 seconds. By following the flow velocity during testing it is possible to derive a 
breath-holding index (BHI) 113, 114  
 
  BHI = [(Vbh – Vr)/ Vr * 100] / s 
    
where Vbh  denotes mean MCA velocity at the end of breathing holding period, Vr  the resting 
MCA mean velocity, and s the seconds of time of breath holding.   
 
Another way to induce a vasodilatory stimulus is to administer acetazolamide, a carbonic 
anhydrase inhibitor, which causes an increase in cellular and extracellular CO2, leading to a 
rise in blood flow velocity  62. The same effect is produced by increasing pCO2 concentration 
in inhaled air 63. 
 
2.2.4  Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) is still a relatively recent invention although it is a highly 
developed and extremely versatile imaging modality. MRI is based on relaxation behavior of 
hydrogen atoms or protons when they are placed in a strong external magnetic field and 
transiently perturbed with radiowaves. When hydrogen atoms with their dipolar magnetic 
fields are in an external magnetic field, the spinning nuclei become aligned with the external 
field, either parallel or antiparallel to it. The parallel alignment is slightly more common, 
leading to a net effect of a weak longitudinal magnetization. Although the alignment is not 
perfect, i.e. the precession movement of protons involves a vector in the plane perpendicular 
to the external field, there is no net transverse magnetization. Radiofrequency pulses used to 
perturb the protons produce transverse magnetization, and the MRI systems may be regarded 
as designed to measure this effect. 
 
Diffusion-weighted imaging 
 
By diffusion-weighting (DW), it is possible to track the molecular motion of water (the 
Brownian movement of protons), i.e. diffusion, by labeling the molecules with very fast-
changing magnetic gradients. The application of a spin echo T2 sequence with two opposed 
equal gradient pulses to create DW was first described by Stejskal and Tanner (1965), but not 
until decades later was the MR equipment advanced enough for clinical application of DWI 
20. 
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The signal intensity (SI) of a DW image may be expressed as 
 
SI = SI0  exp (-b  ADC) 
 
where SI0 is the baseline signal intensity (T2-weighted image, b = 0) and  
 
 b = 2 G2 2 ( – /3) 
 
where b denotes the diffusion sensitivity factor implying the degree of diffusion-weighting,  
the gyromagnetic ratio, G the magnitude of gradient pulses,  the gradient duration, and  the 
time between the two gradient pulses. ADC denotes apparent diffusion coefficient, and it 
gives a measure for diffusion in living tissue. 
 
Diffusion is anisotropic in biological tissues because of natural boundaries to diffusion of 
water 115, 116. Thus, measurement of diffusion is direction-dependent and, in principle, needs 
to be done in several directions 116. A basic approach would be to reconstruct images in which 
the white matter anisotropy is averaged, which would render them to subjective evaluation 
and visualization of areas with diffusion abnormality. Another more quantitative approach 
would be to construct image maps of ADC, cancelling the T2 weighting of basic echo planar 
sequence, which would allow a reproducible assessment of abnormal signal as well as the 
signal of normal-appearing tissue. Acquisition of images in at least three orthogonal 
directions will ensure a rotationally invariant estimate of isotropic diffusion 117. In the course 
of postprocessing the images, their natural logarithms may be averaged to form the 
rotationally invariant resultant image. By applying linear least-squares regression, this image 
and the natural logarithm of the T2-weighted image used as a reference can be fitted to the b 
values, and the negative slope of the ensuing line will represent the average ADC value 
(ADCav). More advanced postprocessing requires the possibility of using the strong 
sensitizing gradients with at least six different spatial orientations. This approach forms the 
basis for the diffusion tensor imaging, which allows estimation of white matter anisotropy 
(fractional anisotropy) and mean diffusivity of the tissue, and thus integrity of the tissue 
microstructure 117-120. 
 
Diffusion and ischaemia 
 
When blood supply to the tissue is diminished and the flow decreases below a critical level, 
which may be below 20 ml/100 g/min, ensuing energy metabolism failure (electrical failure) 
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disrupts electrolyte and water homeostasis (membrane failure) triggering a process that leads 
to cytotoxic oedema 121-124.  The ADC of brain water is seen to decline already within minutes 
after onset of ischaemia 125, 126. Experimentally, the mean diffusivity of brain water declines 
abruptly within the first 15 minutes of stroke, and diminishes for hours to a plateau level that 
may be 60 % of normal 127. Subsequently, the acute drop in diffusivity and the ADC values is 
modified by ensuing vasogenic oedema and increased tissue water, peaking at 1-2 days and 
declining within 4-8 days 128, 129. In parallel, the process of deteriorating cellular integrity 
contributes to the diffusion change. As a result, diffusivity levels are ‘pseudonormalized’ 
within several days after stroke onset, and they continue to rise for days and weeks 130-135. 
Nevertheless, it is notable that the early ADC decrease may also be reversible; still, the 
reversal may not exclude selective neuronal loss in the rescued area 136-139.  At the chronic 
stage, the consistently high diffusivity reflects the few barriers to water movement in the 
lesions after necrotic cell death 130, 135, 140. Especially at the hyperacute stage of ischaemia, 
DWI methodology has become an essential and unique tool of modern imaging. By now, its 
applications are considerably larger and continuously expanding.  
   
Apparent diffusion coefficient (ADC) 
 
Apart from ischaemia, the ADC of tissue water may change in many acute and chronic states. 
Acutely, the process of cortical spreading depression first characterized by Leão in 1944 
involves a propagating wave of cortical depolarization, which is associated with displacement 
of water molecules and transiently lowered water diffusion 141, 142. In the same way, ADC 
changes characterize peri-infarct depolarizations, which accompany ischemic lesions and 
seem to worsen ischaemia, either by number of depolarization waves or their duration 143-145. 
ADC levels have been shown to decrease also in hypoglycemia 146, 147. Epileptic activity may 
give rise to cellular oedema and postictally vasogenic, and DWI changes seem closely 
associated to ictal phenomena 148-150. In brain trauma, it is possible to visualize diffuse 
parenchymal changes not apparent in conventional sequences with DWI, and it may be 
helpful in prediction of outcome in diffuse axonal injury 151-155. In abscesses, ADC values are 
strongly decreased, which may be due to restricted water mobility with high viscosity and 
cellularity within the lesion 156, 157. The most common demyelinating disorder, multiple 
sclerosis (MS) causes a variety of DWI changes: acute demyelinating lesions with infiltrated 
inflammatory cells, vasogenic oedema and demyelination with preserved axons usually 
increases ADC levels but also decreased levels may be encountered, hypothetically explained 
with intramyelinic oedema 158.  In herpes simplex encephalitis the ADC levels may be 
decreased, or rarely increased in cases of vasogenic oedema. In neoplasia, ADC levels may be 
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useful in differentiating some tumours, e.g. low-grade gliomas are associated with higher 
levels than high-grade gliomas or lymphomas 159.  DWI can be informative in acute 
leukoencephalopathies such as posterior reversible leukoencephalopathy, hypertensive 
encephalopathy, and eclampsia, as well as toxic encephalopathies associated with the use of 
cyclosporin, tacrolimus, interferon alpha, or immunoglobulin therapy 160-164. The clinical 
value in this setting is centered on the ability of DWI to differentiate between vasogenic and 
cytotoxic oedema, as the latter may at times represent irreversibly lost ischemic tissue: 
cytotoxic oedema lowers the ADC values and appears hypointense on ADC maps, whereas 
vasogenic oedema increases the ADC values, appearing hyperintense on ADC maps 165-167. 
 
Also chronic processes affecting cellular microstructure would be expected to have an effect 
on ADC values. Longitudinal studies reveal age-related increases in intracranial cerebrospinal 
fluid-filled spaces, mainly at the cost of cortical gray matter volume 168-170. The most common 
parenchymal change in the white matter (WM) degeneration or leukoaraiosis (see p. 42), is 
radiologically a patchy or diffuse attenuation of the white matter which makes it look 
hyperintense on T2-weighted MRI 13. Leukoaraiosis is associated with elevated ADC values, 
which correlate with the degree its severity 171, 172. Furthermore, in cases with more severe 
leukoaraiosis, also the normal-appearing WM has higher ADC levels 171. On the other hand, 
normal healthy aging seems associated with fairly little changes in ADC levels, although 
some frontally weighted increase in diffusivity and decline in fractional anisotropy with aging 
has been detected 173-175.  
 
Perfusion-weighted imaging 
 
Perfusion-weighted imaging indicates depicting microcirculation with MR techniques.  
Perfusion weighting may be based on susceptibility techniques (DSC MRI) or blood 
oxygenation-level dependent imaging (BOLD). The more invasive DSC MRI with either SE- 
or GE-based sequences is commonly used clinically 176-179. Imaging based on BOLD is 
largely utilized for cortical activation studies and more in research purposes. 
 
Dynamic susceptibility-weighted bolus tracking 
 
DSC MRI is performed by combining the simultaneous use of a paramagnetic contrast agent, 
such as gadolinium diethylenetriaminepenta-acetic acid (Gd-DTPA), and a rapid collection of 
the MR signal during the passage of the bolus through the brain 23. Gd-DTPA induces a 
pronounced susceptibility effect and spin dephasing, extending approximately to 5 m from 
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the capillaries into the brain tissue. The susceptibility difference between the contrast agent 
and the brain tissue creates local magnetic field gradients, diminishing phase coherence and 
signal intensity in the tissue surrounding the vessel. Gd-DTPA is cleared from the brain tissue 
in seconds, leading to recovery of signal intensity 180-182. During hypoperfusion, the drop in 
signal intensity is less accentuated and may be negligible in the ischemic brain, which creates 
a contrast between hypoperfused and normal regions. The temporal and spatial resolution of 
the technique have been improved by technical advances, improving signal-to-noise ratio and 
acquisition speed. By now, it is possible to cover a large volume of the brain.   
 
Quantification of the signal change to yield absolute haemodynamic parameters involves 
extensive postprocessing of raw images, and the values seem dependent on the applied 
methodology 179, 183-186. One of the most commonly used has been the deconvolution 
approach, referring to the determination of MTT and CBF from arterial and concentration 
curves in the tissue 26, 187. DSC MRI data analysis for producing quantitative results has 
inherent limitations and thus far has not fulfilled the criteria of strict quantification 183, 188-191. 
Crucially, the quantitative analysis of perfusion data is based solely on the measurement of an 
arterial input function, which has intrinsic requirements difficult to fulfill with DSC MRI 192. 
Furthermore, although the shape of the function can be determined with a fair accuracy, its 
height remains arbitrary 25. Moreover, signal change in relation to the concentration of 
contrast agent is different in brain tissue and larger vessels, and blood hematocrit in 
microvasculature is estimated to be lower than generally in the systemic circulation, and 
individual variation therein would be an additional confounding element 25. The signal is also 
affected by the orientation of large vessels in the magnetic field. Although the method has 
provided reproducible results in human studies, the basic assumptions of the approach may be 
restrictive in study of elderly patient populations with severe cardio- and cerebrovascular 
disease 25, 26, 193-195.  
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2.3  Carotid occlusive disease 
 
Narrowing and occlusion of precerebral arteries subserving the brain was independently 
described by Wepfer and Willis in the 17th century, and the former already appreciated the 
potential of the finding to cause strokes 196. In 1856, Rudolf Virchow described a case of 
carotid occlusion in a patient who had lost vision from one eye 196. As a result of various 
reports and findings, it became evident by the early 20th century that carotid disease was one 
of the central causes of cerebral ischaemia. Development of vascular imaging with 
arteriography contributed to the understanding of carotid occlusive disease that enabled the 
observation of stenosing lesions in vivo197. Clinically, especially the work of C. Miller Fisher 
paved the way for understanding of the clinical significance of occlusive lesions as well as of 
the potential value of restoring the circulation by treatment 198, 199.  
 
2.3.1  Epidemiology and risk factors 
 
The estimated overall prevalence of carotid artery plaques in general population-based studies 
has varied from one-eighth to over one-fourth, depending especially on age 200-203. However, 
the prevalence of stenosis degree considered clinically significant (usually exceeding 50 %) is 
clearly lower, less than 10 %, as a rule 203-209. In two large studies, the prevalence rates of 
clinically significant stenosis in populations above 65 years of age have been 5-7 % in 
females and 7-9 % in males, and the recent meta-analysis ended up with  figures of 12.5 % for 
men and 6.9 % for women in the age group of  70 years or more 204, 205, 210 . In high-risk 
subpopulations, such as males in their late seventies, the prevalence may have been as high as 
28 % 201. In the same way, co-existence of peripheral arterial disease or ischemic coronary 
heart disease increases the prevalence of carotid occlusive disease severalfold 211-215.    
 
Carotid atherosclerosis is associated with several non-modifiable and modifiable risk factors. 
Of the non-modifiable risks, age and male sex have consistently come out in population-based 
studies and meta-analysis 94, 200, 202-204, 209, 210. Of the modifiable risks, arterial hypertension is 
strongly associated with the development of carotid atherosclerosis, especially systolic 
hypertension, according to a few population-based studies 209, 210, 216. Smoking seems to be a 
considerable independent risk factor for CS, along with being a risk for general vascular 
disease 217. Such an overall risk factor is also diabetes mellitus, in particular type 2, which is a 
notable risk factor for CS 218. Physical inactivity is also associated with increasing carotid 
atherosclerosis, although the efficacy of physical exercise as a preventive intervention is not 
unequivocal. Smoking may effectively counteract the benefit from physical activity and 
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optimized diet 219. There is evidence that also renal disease and non-alcoholic liver disease are 
risk factors for carotid atherosclerosis, as well as obstructive sleep apnoea 220-223. 
Homocysteine has been shown to correlate with the severity of carotid atherosclerosis in 
several large studies 224-226. However, the intervention studies with homocysteine lowering 
have failed to show effect in stroke prevention or carotid atherosclerosis 227, 228.  Evolving 
hypotheses involve lifestyle factors such as shift work, which may be associated with earlier 
carotid atherosclerosis 229. 
 
2.3.2  Overall stroke risk 
 
Stenosing lesions in the carotid system may account for 15-20 % of all ischemic strokes 5. 
However, the causality between the mere existence of a stenosing lesion and a stroke is not 
easy to establish, which complicates the evaluation of the true incidence and prevalence of 
symptomatic carotid disease. In a population-based study, the incidence of stroke among 
white Americans with at least a moderate carotid stenosis was estimated as 27 per 100 000 230.  
A few stroke databases have registered the frequency of moderate or high-grade carotid 
stenosis in stroke patients. In the Oxfordshire Community Stroke Project, up to 40 % of all 
anterior circulation strokes had at least a moderate carotid stenosis or occlusion, whereas in 
the Lausanne Stroke Registry not more than 13 % of stroke patients had at least a moderate-
grade stenosis 5, 231.  The pooled analysis of the major randomized CEA trials showed that a 
stenosis exceeding 70 % was detected in 21 % of  patients who experienced TIA or stroke, 
and a moderate stenosis  (50 - 69%) in 25 % of patients 232. 
 
The overall annual risk of stroke attributed to the presence of a carotid stenosis seems fairly 
low, of the magnitude of 1.5 % or less 207, 233, 234. Still, on a population level, it was associated 
with a threefold stroke risk 235. Prevalent cardiovascular disease increases the stroke risk at 
least twofold, raising it to a level around 3 % per year, and the individual risk depends on the 
presence of additional risk factors such as age, hypertension, peripheral arterial disease, and 
diabetes mellitus, in addition to coronary heart disease 236-241. Higher degrees of stenoses are 
associated with a greater stroke risk, approximately 4-8 % 238, 241, 242. The association to the 
stenosis degree is not linear, however, as asymptomatic near-occlusions as well as occlusions 
that have remained silent are associated with a low stroke risk, probably due to sufficient 
collateralization 243-245. Notably, also the stroke etiology is heterogeneous, according to 
NASCET data suggesting cardioembolic or small-vessel etiology in up to 45% of cerebral 
ischaemia in subjects with a significant asymptomatic carotid stenosis 243, 246. 
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Stroke risk in symptomatic carotid disease 
 
The clinical manifestations of a symptomatic state are transient ischemic attacks (TIA) and 
hemispheric strokes (see 2.3.3), and their occurrence dramatically increases the risk of 
vascular events. A high risk of early recurrence after TIA and minor stroke is evidenced by a 
number of studies, and the risk seems to be highest in large-artery atherosclerosis 247-252. A 
very high recurrence risk, weighted towards the very first days, has been described especially 
in patients with carotid stenosis, with a reported rate of 21 % at two weeks 248, 253. Although 
the major endarterectomy trials recruited patients with nondisabling condition and relatively 
late, as a whole, they still show the benefit of early surgery 232. This marked difference in 
stroke risk between recently symptomatic and asymptomatic high-grade stenosis indicates that 
the underlying processes in the stenosis are not static but the plaque may become unstable or 
‘active’. The natural course of stroke risk in the medical arms of the major randomized trials 
has indicated a rapid decline, reaching the level of an asymptomatic stenosis within two years 
81, 83. The risk is lower in women (hazard ratio [HR] 0.79, 95 % confidence interval [CI] 0.64-
0.97), and  higher in patients older than 65 years (HR 1.70, CI 1.28-1.56), higher in patients 
with hemispheric TIA or stroke in comparison to those with amaurosis fugax (HR 1.88-2.33, 
CI 1.38-3.13), and higher in diabetics (HR 1.31, CI 1.05-1.65) and in cases of an irregular or 
ulcerated plaque (HR 1.35, CI 1.11-1.64) 254. 
2.3.3   Pathophysiology 
 
The clinical syndromes caused by ICA disease result from two principal mechanisms that are 
not mutually exclusive: 1) intracranial arterial thrombosis caused by embolism or extension of 
thrombus into the cerebral arteries, and, 2) perfusion failure caused by haemodynamic 
insufficiency 255. The most common cause of arterial narrowing is atherosclerosis  - a chronic, 
indolent, and essentially inflammatory disease process, which has a predilection for large- and 
medium-sized arteries and leads to the accumulation of lipids and fibrous tissue material into 
the vessel wall. A considerably smaller minority of stenosing lesions are caused by arterial 
dissection, post-radiation damage, large-vessel vasculitides such as Takayasu arteritis, or 
connective tissue pathology such as fibromuscular dysplasia 256.  
 
Modes of clinical presentation 
Transient ischemic attack (TIA) is defined as ‘a clinical syndrome characterized by an acute 
loss of focal cerebral or monocular function with symptoms lasting less than 24 hours and 
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which are thought to be due to inadequate cerebral or ocular blood supply as a result of low 
blood flow, thrombosis or embolism associated with disease of the arteries, heart, or blood’ 
257. Proposed definition of stroke has been recently revised as ‘a clinical syndrome 
characterized by an acute loss of cerebral function with symptoms lasting more than 24 h or 
leading to death, and which is thought to be due to either spontaneous haemorrhage into the 
brain substance (haemorrhagic stroke) or inadequate cerebral blood supply to a part of the 
brain (ischemic stroke) as a result of low blood flow, thrombosis or embolism associated with 
diseases of the blood vessels (arteries or veins), heart or blood’ 258. Thus, both manifestations 
are typified by sudden onset and a focal neurological loss, usually maximal intensity at onset, 
whereas distinguished by the duration of symptoms.   
 
The differentiating timeline is arbitrary, based on mutual agreement 259. Actually, TIA and 
stroke form a continuum, as indicated by an identical etiology and prognosis for vascular 
events of patients with focal symptoms lasting less or more than 24 hours 260. Longer duration 
of symptoms is associated with a greater likelihood of a visible ischemic lesion in imaging as 
well as a greater risk of recurrence 261-263. In general, in more than half of TIA cases, signs of 
ischaemia in relevant locations are displayed by DWI or combination of DWI and PWI 264-267. 
As the duration of TIA is generally considerably shorter than 24 hours and new methods of 
imaging allow visualization of hyperacute ischaemia, new definitions and timelines have been 
suggested 268, 269. The recent guideline has adopted a tissue-based definition (‘A transient 
episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischaemia, 
without acute infarction’), and recommends neuroimaging preferably with MRI 270. 
Approximately 23 % of strokes are preceded by TIA, and the subsequent stroke risk may be 
even higher after TIA than after a hemispheric stroke, and the prognosis may be improved by 
active and undelayed measures and investigations in specialist stroke services 271.  
 
Transient monocular blindness, amaurosis fugax, which is usually a short-lived phenomenon 
of monocular visual curtain-like or foggy obscuration of vision lasting seconds to minutes, 
represents a classical form of carotid TIA 272. Often the loss of vision starts from the upper 
part of the visual field, and less frequently appears ascending from below, but it may also be 
patchy or sectorial 272, 273. Altitudinal presentation, speed of onset within seconds, abundance 
of attacks as well as visual loss induced by bright light (‘retinal claudication’) are often 
associated with carotid etiology, whereas constricting pattern of the visual loss or the presence 
of  positive light phenomena may increase the possibility of other etiologies 274-276. Apart 
from carotid etiology, especially the possibility of giant cell arteritis in the elderly should be 
considered, as well as ophthalmological causes such as retinal venous occlusion, vitreous 
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haemorrhage, or optic nerve disease as differential diagnoses 274, 277, 278. In a population-based 
series from the U.S.A., amaurosis fugax accounted for 24 % of carotid TIAs 279.  In 
connection with atheromatous carotid disease, the annual risk of stroke or death after 
amaurosis fugax is estimated as 3-5 %, which is approximately 50 % lower than the risk after 
hemispheric symptoms 257, 280.  
 
Hemispheric symptoms in TIA or stroke caused by a CS may stem from large-vessel 
territories, mainly MCA or sometimes ACA, their branches, or infarctions may occur in the 
watershed or borderzone territories between ACA and MCA or MCA and PCA, or 
lenticulostriate artery level between the deep and superficial perforators, the internal 
borderzone. Watershed infarctions may be more common in association to severe stenoses, 
but any typical patterns may be difficult to identify because of individual variation 281, 282. 
Thus, the hemispheric symptoms of CS are predominantly anterior circulation syndromes. 
The most common manifestations of hemispheric TIAs involve motor and sensory 
dysfunction of contralateral limbs, purely motor dysfunction, sensory dysfunction, and 
isolated dysphasia 272. Contralateral distal arm and hand are the most consistently affected 
parts. A specific albeit uncommon manifestation is ‘limb-shaking TIA’, episodes of irregular 
flapping, twisting, trembling or wavering movement of contralateral arm or leg, which is 
usually associated with severe CS and thought to result from haemodynamic insufficiency 283-
285. The stroke syndromes related to a symptomatic CS overlap with those resulting from 
other embolic sources, and cannot be differentiated on clinical grounds, despite some 
distinguishing features on group level, such as fractional arm weakness in symptomatic CS 
(hand and shoulder differently affected) or reduced consciousness in cardioembolism 286.  The 
clinical manifestations include the whole range of  findings in combinations or in isolation, 
sensomotor hemiparesis, aphasia or dysphasia, apraxia, and neglect. Ocular infarctions may 
also occur, by way of central retinal artery or branch occlusions and ischaemic optic 
neuropathy. 
 
Atherosclerotic plaque and its destabilization 
 
The complex pathophysiological process of the stenosing plaque, during which lipid and other 
blood-borne material accumulates in the vessel wall, involves various pathways of disease 
operating and interacting at the different stages, often silently over years and decades until its 
clinical manifestations appear. Inflammation is one of the central factors throughout the 
process up to the activation stage of the plaque, whereas endothelial dysfunction has an 
integral role especially at the initiating and earlier stages 287. Branching sites with turbulent 
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flow are preferential places for lesion formation, partly mediated by altered mechanical stress 
288. As a rule, the early lesions evolve slowly, and the encroachment of lumen is balanced by 
adaptive vasodilatation and enlargement of the vessel (remodeling). Although the clinical 
manifestations are local, the pathological process is systemic, as evidenced by the frequent 
findings in other vascular beds than the one clinically affected 289. The course of disease is 
highly variable, depending on the acquired risks as well as the genetic risk, and according to 
recent evidence, the course need not be inevitably progressive 290, 291. A prospective 
population-based ultrasound has shown that the early-stage steady and slow progression may 
later on be abrupt and episodic, possibly as a result of disruptive events and healing periods 
292. 
 
Atherosclerosis is essentially a pathology of the intimal layer, leading to accumulation of lipid 
in the intima, collection of inflammatory cells, and proliferation of smooth muscle cells 288, 293, 
294. The first stages (‘fatty streak’ with lipid-containing foam cells) may appear already in 
childhood. The endothelial cells have many physiological functions, forming a selectively 
permeable barrier layer between the vessel wall and flowing blood with tight intercellular 
junction complexes, a non-thrombogenic surface producing effectors that regulate 
inflammatory and immunological stimuli 288. Endothelial injury, promoted e.g. by lipids, 
shear stress and flow disturbances, may lead to impaired vasodilatation and increased 
adherence of leukocytes, impaired fibrinolysis, and finally even to apoptotic denudation and 
severe loss of protective functions 295. Smooth muscle cells may be transformed into 
proliferative forms, and with extracellular matrix elements they may be forming a fibrous cap 
covering the denuded plaque 296, 297. Elevated lipid levels, particularly low-density cholesterol 
(LDL), cause the ingestion of LDL which undergoes oxidation becoming still more 
atherogenic, further impairing the endothelial function, and triggering proinflammatory 
reactions 294. Inflammatory cells, predominantly circulating monocytes, may enter the 
dysfunctional vessel wall by means of adhesion molecules and become macrophages, and 
after engulfing the lipid material, foam cells. Apart from macrophages, also T and B 
lymphocytes as well as mast cells are involved during the atherogenesis. Search for antigens 
in study of immune activation ongoing in the lesions has raised interest in several pathogens 
such as Chlamydia pneumoniae, Epstein-Barr and Herpes simplex type-2 viruses, and an 
association between antibody titers and progression of atherosclerosis has been found 298. 
However, there is little prospective evidence that the antibodies predict vascular risk, and the 
intervention trials with antibiotics have not been successful 299. It is possible that advanced 
plaques gather bacterial DNA and no single agent has a causative role although microbes may 
have etiopathogenetic role in the process 300.  
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Activation or destabilization of the atherosclerotic plaque, turning it into a symptomatic 
phase, is difficult to predict. As the plaque grows and stenosis degree increases, thrombus 
formation is more common, giving more easily rise to distal embolization from the stenosis, 
and the risk is increased in the presence of ulceration or eccentricity of the plaque 301. Other 
mechanisms of symptom generation are local occlusion by a thrombus, which is more 
infrequent, and occlusion of small vessel origins by the growing plaque 293.  Several minor 
studies comparing plaque pathology in symptomatic and asymptomatic stenoses have 
implicated a significant association between symptoms and plaque rupture, thinning of fibrous 
cap, and infiltration by macrophages and T cells 10.  A large histopathological study 
confirmed the high degree of inflammatory infiltration and cap rupture in symptomatic 
plaques as well as the association between the pathology to time course since the last event 
302.  The components of the fibrous cap may be depleted by various matrix-degrading 
metalloproteinases and other proteases expressed by inflammatory cells and smooth muscle 
cells, predisposing to rupture. The lipid core of the plaque contains high concentrations of 
tissue factor, which is very thrombogenic in contact with blood and presented especially by 
apoptotic macrophages 303. The blood contact is followed by deposition of thrombocytes, and 
the ensuing thrombosis is dependent on the balance between procoagulant and anticoagulant 
activity in the blood. Adhesion molecule expression has been suggested to be associated with 
symptomatic state, either as correlating positively to the endothelial expression or negatively 
to the expression in intima-media 12, 304.  Apart from the mechanism of cap degradation, the 
other mechanism of plaque rupture is physical force, predisposing sites with high structural 
stress to disruption. 
 
Identification of the vulnerable atherosclerotic plaque is challenging. By now, it is accepted 
that the composition of the lesion may be the major determinant of the clinical manifestation 
of atherothrombosis rather than the mere grade of stenosis or volume of the plaque. This has 
sparked an interest in the novel methods of imaging the plaque and created a trend of 
molecular imaging. Considerable progress is expected in the next few years by a multimodal 
approach to patients with CS, by combining clinical history and epidemiology, versatile 
imaging, and biochemical markers for better identification of vulnerable plaques 305. 
 
Coagulation, haemostasis, and haemorheology 
 
Coagulation of blood and haemostasis, arrest of blood flow, are the very essence of 
atherothrombotic strokes. Clinical thrombosis involves blood flow, platelet-vessel 
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interactions, and the coagulation system. The phenomenon of blood coagulation is a highly 
interwoven interaction of platelet activation, fibrin formation for the backbone of the 
thrombus, and fibrinolysis for its breakdown. The intertwined elements need to be considered 
together to have an overview of the clotting process (for a simplified outline, see Figure 5) 306, 
307. The intricate balance between procoagulant and anticoagulant or fibrinolytic activity in 
blood could be crucial in generation of symptoms in cerebrovascular disease, and appropriate 
haemostatic markers would be of interest in identifying and possibly treating high-risk 
groups. 
 
Several potential markers measurable in vivo are produced during the cascades. One of the 
key players is thrombin which induces conversion of fibrinogen into fibrin at the end of the 
cascade, but it has multiple actions as a procoagulant activator of several coagulation factors 
and platelets as well as an anticoagulation effect through protein C activation, which also 
enhances fibrinolysis 306, 307. When thrombin is cleaved from prothrombin, either by intrinsic 
or extrinsic activation system, prothrombin fragments 1 and 2 (PF 1 and 2) are released into 
the plasma, reflecting the degree of prothrombin activation and thrombin generation. The 
predominant thrombin inhibitor is antithrombin III, the most important inhibitor of 
coagulation proteases, and the forming thrombin-antithrombin complex has also been used as 
an assessable indicator of thrombin activity 308. Fibrinolytic activity is dependent on the 
conversion of plasminogen to plasmin, in which tissue-type plasminogen activator (t-PA), of 
endothelial origin, appears to have a central role 306, 309, 310. t-PA activity is regulated by 
several inhibitors, especially type 1 plasminogen activator inhibitor (PAI-1).  Fibrin cleavage 
by plasmin produces several degradation products, such as fibrinopeptide A and B as well as 
cross-linked D-dimer, which is considered specific to fibrin polymer 306, 311. In prospective 
studies, PF 1 and 2 levels have predicted cerebral and cardiac ischemic events and t-PA 
antigen levels have predicted stroke, and especially fibrinogen has been shown to be an 
independent risk factor for stroke and its severity 312-317. Still, the haemostatic markers have 
not yet produced useful prognostic variables for routine clinical use, partly for methodological 
reasons 270, 318.  
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Figure 5. Outline of coagulation cascade (HMW = high molecular weight kininogen; PL = 
phospholipid; TPL = tissue thromboplastin) 
[according to Wessler & Gitel, N Engl J Med 1984;311:645-52, with permission].   
 
 
Flow characteristics of blood, rheology, determine its ability to perfuse the brain; 
consequently, haemorheology is an important variable also in cerebral ischaemia. Blood is a 
non-Newtonian fluid, the viscosity of which in normal circumstances mainly depends on red 
blood cell mass, hematocrit (Hct), and fibrinogen, which constitutes the largest quantity of 
high-molecular-weight proteins in the plasma 319. Not only high fibrinogen but also high Hct 
can be regarded as a risk factor for stroke. In humans, CBF is inversely correlated with blood 
viscosity, although autoregulation to some extent counteracts the fluctuations and protects the 
brain 320, 321. At the acute stage, haemorheological abnormalities are common, and they may 
partly be due to non-specific acute-phase changes such as fibrinogen increase but in many 
cases they may just as well be chronic 322-324. All the same, elevated Hct in acute stroke may 
be associated with reduced reperfusion and tissue survival rates and increased mortality 325-327. 
Despite the potential effect on CBF, acute intervention trials aiming at haemodilution in acute 
ischemic stroke have not proven to improve survival or outcome 328.   
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In the context of carotid stenosis, platelets have essential functions not only in primary 
haemostasis and in acute vascular events but also in endothelial repair and during the 
formation and growth of atherosclerotic plaques. The mere presence of atherosclerotic plaque 
may lead to platelet activation 329-331. The degree of arterial stenosis is an important factor in 
recruiting platelet deposition, contributing to the instability of the forming platelet-rich 
thrombus at the stenotic site 332. Also, the contribution of thrombin generation in an 
experimental model of shear force-induced thrombosis and its inhibition during high grade 
stenosis-associated thrombus formation demonstrate that the growth of these thrombi is 
indeed thrombin-dependent 332, 333. Clinical observations supporting this view have been 
reported 334, 335. Accordingly, a disturbed balance between the finely regulated procoagulant 
and fibrinolytic activity in blood could contribute in the process when an asymptomatic CS 
turns into a symptomatic one. The stability of the atherosclerotic plaque could also be 
regulated by local fibrinolytic activity in the plaque macrophages. As a potent activator of 
matrix metalloproteinases, plasmin could contribute to plaque instability. Urokinase-like 
plasminogen activation is co-localized with thrombosis on the surface of an atherosclerotic 
plaque, and the theory of plasminogen system involvement is supported by extensive studies 
in knock-out animal models 336, 337. Furthermore, plasminogen activators and their regulators 
are upregulated in failing arterialized venous grafts, underlining the possible role of the 
fibrinolytic system in the events 338. Also haemorheology may have an especially important 
role in the high-pressure setting of carotid artery flow and through shear stress forces affect 
haemostasis, thrombosis, and the growth of plaques. The association between haemorheology 
and atherosclerosis may be more obvious in men 339. 
 
Cerebral haemodynamics 
 
The CS could give rise to ischaemia by cutting down the blood flow to the brain and causing 
haemodynamic insufficiency, which used to be a popular explanation for cerebral events 293. 
However, the blood flow through the stenosis is not affected until the stenosis degree exceeds 
50 %, and substantial reduction does not occur until the high-grade levels (Figure 6) 340.  
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Figure 6. Changes of pressure gradient and flow through progressive luminal obstruction of a vessel 
(reproduced with permission from Hademenos et al., Stroke 1997;28:2067-2077)
 
 
 
By way of autoregulation, the cerebral perfusion pressure may still be maintained within 
normal limits. A considerable drop in blood pressure does not often cause cerebral symptoms, 
and when occurring, the symptoms tend to be nonfocal, such as presyncopal signs. However, 
if the collateralization is defective as a result of anatomy or acquired disease, autoregulatory 
reserves may be exhausted so that CBF is affected, causing a gradual rise in oxygen extraction 
fraction, and probably leading to an increased stroke risk, at least in symptomatic stenoses or 
occlusions 75, 341-345. Haemodynamic compromise is not regarded as a major pathogenetic 
mechanisms of ischaemia in carotid occlusive disease, but in a minority of patients the pattern 
of ischaemia follows borderzones between arterial territories, as a potential sign of a 
haemodynamic etiology 282, 346. The radiological diagnosis of a borderzone or watershed 
infarction is not accurate, not only because of the considerable variation of watershed zones 
but also because some of these infarctions apparently result from embolism 293. Nevertheless, 
prevalence of carotid occlusive disease is high in patients with an observed borderzone 
infarction, both cortical and especially internal 347. Haemodynamic etiology is suggested also 
by precipitation of stroke symptoms by sudden haemodynamic change such as systemic 
hypoperfusion during cardiopulmonary bypass, severe haemorrhage, or as a result of 
autonomic failure or overzealous antihypertensive treatment 348-350. 
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Both embolic and haemodynamic mechanisms may in fact interact: haemodynamic factors 
may determine whether an embolization leads to occlusion of vasculature or is ‘washed out’ 
with reperfusion of the tissue 347, 351. This could partly explain the variance of outcome in 
carotid occlusions, when the embolus either causes a permanent vessel occlusion or is 
fragmented with reperfusion of the vessel, and the co-occurrence of embolic and 
haemodynamic stroke patterns 347. Overall, considering the diagnostic difficulties, it is 
currently held that the significance of low flow in cerebral ischaemia is not fully understood 
293. It is also notable that in discussions ‘symptomatic’ state usually denotes focal clinical 
manifestations, whereas long-term effects, such as the effect of potentially increased MES 
loads over longer periods of time because of diminished washout, or chronic relative 
hypoperfusion, are controversial or unknown. 
  
White matter changes 
 
Leukoaraiosis (LA) or white matter lesions (WML) refer to bilateral and either patchy or 
diffuse areas of hypodensity of the WM on CT or hyperintensity on T2-weighted MRI  13, 352. 
Its frequency in older patient groups has ranged between 21% and 100% depending on the 
imaging method and the study population 353. In a study population representing young and 
healthy working-age individuals, the prevalence of WML was reported as 5.3 % 354. Overall, 
the figures are relative as they are based on variable rating scales, and the results are 
dependent on the applied MR technology, the very basis of WM research 355-358. Consistently, 
the risk of developing WML increases with age, and the finding is often referred to not only 
as WM lesions or hyperintensities (WMH) but also as age-related WM changes 353, 359. Still, 
WML are seen also in younger individuals and stroke patients 354, 360, 361. Customarily, WMH 
have been divided into periventricular (PVH) and deep hyperintensities (HI) by topography, 
and punctate, early confluent or confluent by nature and extent. A population-based 
topographical study on healthy individuals aged 60 - 64 has confirmed that the periventricular 
WM has the highest frequency of hyperintense lesions, closely followed by deep HI 
particularly in occipital and frontal lobes, some degree of WMH being present in every 
subject 362. Susceptibility to development of LA and the lesion volume seem genetically 
influenced 363, 364. Vice versa, pronounced LA is the hallmark of several hereditary diseases, 
such as leukodystrophies, and especially CADASIL (cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy) 353. The tendency of WML to 
progress over time seems associated with the initial severity of the lesions, presence of 
lacunes and previous strokes, diabetes and blood glucose levels, and increases in diastolic and 
systolic blood pressure 365-369. Also elevated homocysteine levels correlate with the degree of 
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LA, and homocysteine has been considered a marker of endothelial dysfunction 370-372. Even 
birth parameters such as lower birth or placental weight have been suggested to affect the 
proneness to LA 373. 
 
In LA pathology, the most conspicuous findings are gliosis, axonal loss, myelin pallor, and 
enlargement of perivascular spaces 352, 374. The ischaemic appearance is most consistent in 
extensive confluent lesions, whereas PVH appear rather non-ischaemic with subependymal 
gliosis and ependymal discontinuity, enhanced by disturbed flow of cerebrospinal fluid 14, 375. 
In pathological studies, chronic ischaemia, myelin degradation, apoptosis, and axonal 
transport failure have appeared as integral parts of pathophysiology 376-378. Thus, chronic 
cerebral ischaemia and hypoperfusion have been regarded as the main etiology for LA, but its 
pathogenesis remains incompletely understood and the terms controversial 14. The cerebral 
WM is supplied mainly through long penetrating arteries stemming from branches of the 
major cerebral arteries on the pial surface with few anastomoses. In cases of small vessel 
disease, the structure of the vessels changes with arteriolosclerosis, hyaline thickening, 
elongation and increased tortuosity, leading to altered blood supply and either localized 
necrosis and cavitation or diffuse rarefaction, LA 14, 379, 380. In terms of pathology, LA may be 
considered a diffuse manifestation of small vessel disease. It may be accompanied with focal 
isolated lacunar infarctions, and either focal or diffuse manifestation can predominate. 
Notably, small vessel disease occurs also without arterial hypertension, as does LA 14, 379. 
Consequently, it has been postulated that mere alterations in blood pressure regulation could 
contribute to the pathogenesis of LA, since patients with LA display more variation in BP and 
possibly poorer autoregulation 14. CBF reductions have been detected in LA regions, and even 
a steal phenomenon has been described 381-384. However, it is possible that the decrease in 
CBF is an effect rather than a cause, or an epiphenomenon. Still, lower CBF has been 
reported also in the normal-appearing white matter of subjects with LA, in the same way as 
lower fractional anisotropy and higher mean diffusivity and ADCav values on diffusion tensor 
imaging and DWI 120, 171, 384.  
 
Apart from ischemic hypothesis, it has been suggested that disruption of blood-brain barrier 
could lead to WM damage through extravasation of plasma proteins 385, 386.  A unifying theory 
could be offered by endothelial dysfunction and a systemic failure in arteriolar function 370, 
387. 
 
Clinical consequences of LA are evident and manifold, although LA may at times be 
considered asymptomatic or its effects go unnoticed. Firstly, it is associated with cognitive 
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impairment that is especially related to frontal-lobe performance with deficits in executive 
functions and information processing speed 388-394. Some data suggest that WM 
hyperintensities predict dementia, and it has long been evident that LA often coexists and 
interacts with Alzheimer’s disease, sharing many risk factors with it and modifying the 
overall cognitive profile of the patients 395, 396.  LA is also associated with late-onset 
depressive symptoms 397. Subjects with advanced LA have problems with gait and a poorer 
balance, and there is evidence of an increased risk of falls and urinary complaints 398-400. LA is 
a risk factor for stroke and vascular events, symptomatic haemorrhagic transformation after 
thrombolysis of acute ischemic stroke, and poorer outcome and death after stroke 401-406. 
 
In a high-grade CS, ensuing relative hypoperfusion could in principle be associated with 
subclinical changes in the parenchyma, especially in the WM. Presence of LA with a carotid 
stenosis has predicted stroke events, especially lacunar, during follow-up 407, 408. At least 
partly reversible metabolic changes such as diminished N-acetyl aspartate and elevated lactate 
in MR spectroscopy in hypoperfused ipsilateral brain have been described in patients with CS, 
but the results are variable 409-411. Experimentally produced chronic hypoperfusion has caused 
widespread changes in the WM and cognitive disturbance in animals 378, 412. Consequently, an 
increased propensity to ischemic WM degeneration could be expected in a high-grade CS 
with a haemodynamic compromise also in humans, and the decreased reactivity and perfusion 
in LA could make the WM more susceptible to transient ischaemia and myelin rarefaction 381, 
384. Recent data have given support to the hypothesis, as well as suggested an association 
between the carotid plaque characteristics, namely intraplaque haemorrhage and lipid content, 
and WM hyperintensities 413, 414.  
 
Cognitive function 
 
As a risk factor for stroke, CS is inevitably associated with cognitive decline and dementia. 
CS is a known risk factor for lacunar infarctions, part of which are silent, and they are known 
to interfere with cognitive performance 415.  Also subclinical parenchymal changes associated 
with continuous silent microembolization or a haemodynamic deficit in a high-grade CS 
could give rise to cognitive impairment, although the stenosis would clinically be categorized 
as an asymptomatic one. Indeed, in two cross-sectional studies, the subjects with high-grade 
asymptomatic carotid stenoses were found to have impaired cognition in comparison with 
subjects without stenoses 416, 417. The study with a more detailed neuropsychological protocol 
found the impairments in the domains of attention, psychomotor speed, memory, and motor 
functioning. Apart from lacunar infarctions, the CS group had no more MR lesions, which did 
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not support the notion of silent embolization 417. Also the other study with a follow-up design 
found the association regardless of MR findings and after adjustment to vascular risk factors, 
supporting the notion of asymptomatic CS as an independent risk factor for cognitive 
impairment and decline 416. A recent report suggested that reduced cerebrovascular reactivity 
could explain some cognitive decline in these patients 418.   
 
Impaired haemodynamics due to heart failure is associated with impaired cognition, in a 
similar way, and cerebral hypoperfusion may precede and even contribute to onset of clinical 
dementia 419-421. There is also some evidence that the effect of constitutional hypotension 
might not always be offset by autoregulation but give rise to cognitive deficits, primarily 
those of attention and memory 422. Thus, the fraction of patients with a high-grade CS and 
insufficiently compensated cerebral circulation could be expected to be at risk of cognitive 
effects. 
    
 
2.4  Treatment of carotid stenosis  
 
The understanding of the carotid pathology as an etiology of stroke improved greatly during 
the last century, which paved the way for the development of efficient medical treatment of 
the risk factors associated with carotid atherosclerosis as well as the surgical and 
endovascular techniques for stroke prevention.  Medical treatment may be regarded as the 
backbone of treatment for all patients whereas carotid interventions are selectively indicated. 
 
2.4.1  Carotid endarterectomy (CEA) 
 
The first successful surgical removal of the stenosing plaque (CEA) was performed in 1953 
but not reported until 1975 423. The main impetus to a more widespread use were given by the 
early reports, leading eventually to a vast and variable surgical practice 424, 425. Five 
randomized controlled trials have been performed on the safety and efficacy of surgery on 
symptomatic CS 81, 83, 426-430. The early two studies with limited sample sizes did not produce 
conclusive evidence on the value of surgery, unlike the latter trials, of which the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid 
Surgery Trial (ECST), complemented with a minor population from the Veterans’ 
Administration Cooperative Symptomatic Carotid Stenosis Trial, altogether with 6092 
patients and 35 000 years of follow-up, form the main body of evidence which the present 
guidelines and practice are largely based upon 232.  
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In symptomatic CS, appropriate CEA is an efficacious means of prevention. In symptomatic 
patients with 70-99 % stenosis, CEA can decrease the risk of stroke by more than 60 % 
(relative risk 0.39, CI 0.28-0.51), and in those with moderate stenosis (50-69%) by 25 % 
(relative risk 0.75, CI 0.56-0.94) 254. Absolute 5-year reduction of  risk of any stroke or death 
was 15.3 % (CI 9.8-20.7) in patients with 70-99 % stenosis and 7.8 % (CI 3.1-12.5) in 
patients with 50-69 % stenosis. No 5-year benefit was seen in near-occlusions, however, 
possibly indicating the presence of good collateralization, neither did patients with < 50% 
stenosis benefit from surgery. Risk reduction figures were essentially similar for disabling 
stroke. Of the subgroup analyses of pooled data, it appeared that in addition to the degree of 
stenosis, also age, sex, and time from the last event modified the efficiency. Men had the most 
benefit as well as patients of age 75 years or more and those randomized within two weeks 
since symptoms. Women with a stenosis of moderate degree (50-69 %) did not benefit from 
surgery, partly because of lower stroke risk on medical treatment and higher surgical risks, 
whereas in the high-grade stenosis group, the benefit was clear 431.  Timing of CEA has 
become an important factor as the stroke risk is known to be high in the early phase after 
symptoms, and the benefit appears to wane after two-week delay, essentially vanishing in 
moderate stenoses after this period and in high-grade stenoses by three months. The 
guidelines have adopted this recommended timeframe, although it is obvious that at present 
the delays tend to be longer 432-434. The operative risks are highest in emergency CEAs, but 
early CEA in stable patients with minor stroke or TIA does not seem to have higher risk than 
delayed surgery 435. In the pooled analysis, the perioperative risk of stroke or death was 6.2 % 
232. 
 
In asymptomatic CS, the benefit of surgery is considerably smaller. Of altogether seven trials, 
three major comparable ones were included in the latest systematic review 8, 436-438.  In this 
review, the relative risk reduction in the surgical group was 31 % (RR 0.69, CI 0.57-0.83) for 
any stroke or death. Absolute risk reduction was 3.0 % over a mean follow-up of 
approximately 3 years. The overall perioperative complication rate was 2.9 %. Subgroup 
analyses were performed in the two large trials showing a greater benefit from CEA in men, 
and in women the benefit within the follow-up time was not significant 8. In contrast to 
symptomatic CS, the benefit of surgery in asymptomatic CS did not appear proportional to the 
degree of stenosis or age, but the data were considered insufficient 8, 232.  
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2.4.2  Medical treatment 
 
The mainstay of secondary prevention is antithrombotic treatment together with modification 
of risk factors 439. Antiplatelet drugs are used on the basis of symptom-based stroke 
prevention trials, mainly acetosalicylic acid (ASA), clopidogrel, or dipyridamole, mostly in 
combination with ASA. No stroke prevention studies have focused exclusively on patients 
with carotid stenosis, and the evidence is elicited from non-cardioembolic stroke prevention 
studies. In secondary prevention, ASA may reduce the relative risk of vascular events by 13-
22 %, and the effect may even be doubled by combining extended-release dipyridamole 440-
442. Clopidogrel is not inferior to the combination and may be better in comparison with mere 
ASA for vascular events 443, 444. In the setting of a symptomatic CS, administration of ASA is 
associated with less microemboli, and also clopidogrel given prior to CEA has reduced 
postoperative embolization rate 103, 445. Also combination of ASA and clopidogrel seems to 
reduce MES in recently symptomatic CS but cannot be recommended owing to the reported 
increase in major bleeding risk in stroke patients 105, 446, 447. ASA has been recommended even 
for primary prevention in patients with asymptomatic CS, based on the regular ASA use in the 
medical arm of the major carotid trials, in which the ASA use was associated with fewer 
myocardial infarcts 448. Anticoagulants are effective in stroke prevention in patients with atrial 
fibrillation, but in non-cardiogenic stroke anticoagulation provides no extra benefit over 
antiplatelet treatment 449, 450. In carotid stenosis, anticoagulation has been used in the clinical 
practice in cases of crescendo TIA or progressing stroke, or in an assumed symptomatic low-
flow state, without specific evidence to support the practice.  
 
Statins (3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors) used for lipid-lowering in 
patients with coronary heart disease have considerably reduced the incidence of fatal and non-
fatal stroke, albeit that cholesterol has previously been considered a weak risk factor for 
stroke 451. A comprehensive meta-analysis of the earlier statin trials up to 2003 found a 
relative risk reduction of 21 % for stroke without heterogeneity between the studies, and a 
consistent correlation between low-density lipoprotein cholesterol  decrease (LDL-C) and 
stroke risk reduction as well as progression of carotid intima-media thickness 452.  The only 
statin trial designed primarily for secondary prevention of stroke showed a clear risk 
reduction of both fatal and non-fatal strokes with an aggressive treatment (atorvastatin 80 mg) 
in patients with TIA or minor stroke and no history of coronary heart disease 453. Apart from 
the LDL-C reduction which seems to be the main driving force behind the decrease in stroke 
risk, statins may act through anti-inflammatory, antiatherothrombotic, neuroprotective, and 
plaque-stabilizing properties and effect on endothelial function, which might be beneficial 
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especially in CS 452, 454-456. In the atorvastatin stroke trial,  a secondary analysis supported the 
notion of special benefit in the carotid stenosis subgroup with a 56 % reduction of subsequent 
carotid revascularization in the group randomized to atorvastatin 457. Consequently, although 
the absolute stroke risk reduction with statins is modest in general, they are an essential part 
of medical treatment in CS patients, at least in those with less than optimal lipid profile. 
 
Antihypertensive treatment is needed in the majority of patients with CS, and it is one of the 
cornerstones of medical treatment. There is evidence that the choice of antihypertensive agent 
may make a difference in secondary prevention, centering on the renin-angiotensin system: 
treatment with angiotensin-converting enzyme (ACE) inhibitor perindopril with indapamide 
was associated with better outcome in patients with previous stroke or TIA, and treatment 
with angiotensin receptor blocker losartan was associated with 25 % relative risk reduction 
for stroke in comparison with patients on atenolol despite identical blood pressure control 458, 
459. Also candesartan has been associated with significantly less non-fatal strokes 460. Based 
on the evidence, prevention guidelines have adopted the recommendation to favour ACE 
inhibitors or angiotensin receptor blockers in antihypertensive treatment, if possible 432. Since 
there are no antihypertensive trials specifically in patients with CS, the particular benefit in 
this group is not known. However, some preliminary findings support the antiatherogenic and 
endothelial function improving effect of ACE inhibition also in human carotids 461.  
 
2.4.3  Effects of CEA on the functioning of the brain 
 
CEA may be considered protective of cerebral functions, as it is an effective means of stroke 
prevention. Still, it is also a risk factor for stroke, since a complicated course of surgery may 
produce the unwanted result, especially in unstable patients 435. The frequency of stroke and 
death in recent large reports have been not dissimilar to the pooled analysis of the previous 
large CEA trials, being 5.6-7.9 % for those operated on for TIA or stroke 232, 462. Apart from 
frank strokes, perioperative ischaemia is more often clinically silent, and postoperative DWI 
lesions are detected in at least one-tenth of patients 16, 17, 107, 463, 464.  Nevertheless, cognitive 
decline may not be recognized in this group in the clinical practice.  
 
At least transient cognitive decline seems to occur in a substantial proportion of patients 
undergoing CEA 16-18, 465, 466. Postoperative decline has been more common in aged 
individuals, diabetics, and carriers of apolipoprotein E-4 allele, and it has occurred regardless 
of whether general or regional anesthesia was applied 18, 465, 467. The decline may mostly be 
DWI-negative 17. All the same, it is often attributed to diffuse perioperative embolization or 
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haemodynamic instability or dysregulation 468, 469. However, the studies have had limited 
sample sizes to verify a relationship between HITS or dysregulation and cognitive impairment 
466, 468-470. Despite a single positive report on the association of gliofibrillar protein S-100B 
levels with subtle cognitive decline, the biochemical markers have not been useful indicators 
in CEA 471-473. Not only embolization and hypoperfusion but also postoperative cerebral 
hyperperfusion may be associated with long-term cognitive decline that can be detectable 
without structural signs of damage in MR imaging and be persistent over a half-year follow-
up 474, 475.  Overall, the long-term course and significance of the postoperative cognitive 
decline is undetermined.  
 
Since the advent of carotid endarterectomy as an established treatment method, many subjects 
having had carotid surgery have themselves reported subsequent cognitive improvement, 
which has probably been readily explained by improved cerebral circulation after 
revascularization.  However, the results of the earlier studies attempting to objectively 
evaluate the neuropsychological effects of the carotid surgery and the improvement of 
perfusion have reported highly controversial results, the early studies tending to report 
improvement, the recent ones being more neutral or reporting decline 15, 476. The variance of 
results has been partly explained by methodological problems, e.g. lack of controls, 
insufficient control of confounding factors such as learning or practice effect, heterogeneity of 
samples, as well as natural recovery from the index event, and finally, the number of patients 
in most of these studies has been limited. Laterality of cerebral functions also brings about 
variation 108. Furthermore, it is possible that the proneness of asymptomatic and symptomatic 
populations to cognitive change is different. The earlier studies rarely correlated their findings 
to other functional methods such as imaging. Even in a study reporting postoperative 
cognitive improvement and cerebral circulation, the finding could not be attributed to 
increased cerebral blood flow 477. Judging by the data available at the time, a systematic 
review concluded a decade ago that although majority of the studies reported a postoperative 
cognitive improvement, no conclusion can be drawn on the effect of CEA on cognition 
because of the methodological issues 15. A recent systematic review found few studies 
published after 1990 showing any clear improvement in cognition after CEA, and ended up 
with the same conclusion that no substantial effect on cognition can be elicited, although most 
studies are still underpowered with a high risk of false negative results 476. Yet, two small 
studies utilizing functional imaging (SPECT) and a moderate-sized study with TCD 
diagnostics, all with limited cognitive examination batteries, suggest the existence of a 
haemodynamically compromised subpopulation that could benefit from CEA in terms of 
cognition 478-480.  
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3.  AIMS OF THE STUDY 
 
The purpose of this study was to combine new MR methodology to find out whether a high-
grade carotid stenosis, clinically symptomatic or asymptomatic, and surgical treatment of 
such a stenosis are associated with changes in brain microcirculation and diffusion, and 
whether the changes are associated with the neuropsychological performance of the patients.  
 
The aims can be divided in four sections: 
 
I      to evaluate brain diffusion with MRI in asymptomatic and symptomatic patients with 
carotid occlusive disease before and after endarterectomy, and to compare the results with 
those of healthy controls [paper I] 
 
II     to evaluate cerebral perfusion and vasoreactivity in patients with carotid occlusive 
disease before and after endarterectomy, and to determine if the responses differ in 
symptomatic and asymptomatic patients, using MRI and transcranial Doppler ultrasound 
(TCD)  [paper II] 
 
III    to evaluate cognitive functions in patients with carotid occlusive disease and compare 
their performance with that of healthy controls; to evaluate the cognitive change after 
endarterectomy  and analyze whether the change is associated with cerebral perfusion or 
diffusion findings or whether the change is different in asymptomatic and symptomatic 
subgroups [paper III] 
 
IV    to find out if some parameters of blood coagulation, fibrinolysis and haemorheology 
differ between asymptomatic and symptomatic patients with a high-grade stenosis [paper IV]
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4.  SUBJECTS AND METHODS  
4.1  Subjects 
 
The study protocols for the Helsinki Carotid Endarterectomy Study (HeCES) were approved 
by the Ethics Committee of the Departments of Neurology and were carried out according to 
the principles of the Declaration of Helsinki and the institutional guidelines. We recruited 92 
consecutive consenting patients fulfilling the inclusion criteria who had been referred to the 
neurological or the surgical department of our university teaching hospital for treatment of 
their high-grade carotid stenoses. Six patients had both carotid arteries operated in the study, 
making the total number of endarterectomies 98. The subjects had to be independent in daily 
life (modified Rankin scale < 2), without potential cardiogenic origin of emboli, with no 
history of previous ipsilateral carotid endarterectomy (CEA) or radiotherapy, and with a 
surgically accessible carotid stenosis measured 70 % or more in digital subtraction 
angiography according to NASCET criteria 426. After giving their written informed consent, 
they underwent a thorough clinical examination and detailed interview by a stroke neurologist 
for classification and assessment of risk factor profile (Table 1).  
 
The total study population was used for the laboratory analyses in the study IV.  Apart from 
the neurological symptoms and the female predominance in the asymptomatic group, 
demographics of the two groups did not differ (Table 1). On the whole, 74 had had cerebral 
symptoms: 54 had had a recent minor hemispheric stroke, TIA or amaurosis fugax in the 
territory of the stenotic artery (median 41 days, interquartile range 22-80 days), whereas in 20 
cases the symptoms were attributed to another cerebral territory, rendering the operated 
plaque asymptomatic (median 106 days, interquartile range 59-198). The remaining 18 
patients were totally free of cerebrovascular symptoms.  In the symptomatic plaque group, 19 
patients had an ongoing anticoagulant medication, and so had one patient in the ‘other 
symptoms’ group. The average time from symptoms to operation was 77 days (median 58) in 
the non-anticoagulated and 55 (median 38) in the anticoagulated patients.  The data of the 
patients and their removed plaques were analyzed comparing both symptomatic vs. 
asymptomatic patients as well as plaques. Separate analyses were made for patients with and 
without anticoagulation and for patients on or off statin or ACE inhibitor treatment . 
 
The populations of the substudies I-III were limited by the availability of scanning facility and 
the study neuropsychologist, or by the presence of a contraindication to imaging, as well as 
the patient’s individual consent to participate in the substudies 481. 
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Table 1.  Demographic and clinical profiles of asymptomatic and symptomatic subgroups in study IV 
   (n = 92;  means and 95 % confidence intervals for continuous variables). 
   
                                                             TOTALLY                 SYMPTOMATIC,         SYMPTOMATIC  
                    ASYMPTOMATIC                 OTHER                         PLAQUE 
                                                                (n=18)                                  (n=20)                               (n=54) 
________________________________________________________________________________ 
 
   Gender: female/male (%)          10/8 (44%) *  7/13 (65 %)  15/39 (72 %) 
   Age (years)         65.0 (60.7-69.2)    65.0 (61.5-68.5)     64.4 (62.1-66.7) 
 Body Mass Index (kg/m2)             26.5 (24.3-28.7)           26.1 (24.5-27.7)              27.8 (26.6-29.0) 
   Carotid stenosis (%, NASCET)     76.3 (72.7-79.9)           76.7 (73.4-80.1)  78.7 (76.2-81.2) 
   Coronary heart disease 8 (44 %)   9 (45 %)         17 (31.5 %) 
 Peripheral arterial disease    5 (28 %)     8 (40 %)       15 (28 %) 
 Arterial hypertension                       11 (61 %)  13 (65 %)         38 (70 %) 
 Diabetes mellitus    4 (22 %)   6  (30 %)        13 (24 %) 
 Dyslipidemia    9 (50 %)    16 (20 %)        32 (59 %) 
 Smoking 
 Current    4 (22 %)     7 (35 %)        17 (31 %) 
 Former  10 (56 %)  10 (50 %)         27 (50 %) 
 Stroke         -    13 (65 %)        26 (48 %) 
 Preoperative TIA         -  13 (65 %)        28 (52 %) 
 Statin use   7 (39 %)             10 (50 %)        22 (41 %) 
 ACE inhibitors   2 (11 %)     6 (30 %)         12 (22 %) 
 Antiplatelet agents  15 (83 %)    16 (80 %)         32 (59 %) 
 Anticoagulation   1 (5.6 %)       3 (15 %)        21 (39 %) 
 Time since symptoms (days)       -  158 (75-240)         55 (42-67) 
 
 
    (* p < 0.05, 2 test) 
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4.2  Controls 
Two sets of control populations were selected. For the study I, the age- and sex-matched 
controls (n = 45, mean age 61.9 ± 10.8, range 42-85 years) were chosen from a strictly 
healthy population. They had to fulfill the following criteria: no symptom, sign or history of 
any neurological disease or a systemic disease with a potential brain involvement; no family 
history of dementia or multiple sclerosis; no regular medication except for hormonal 
substitution or topical therapies, and no history of excessive alcohol intake over longer 
periods. All subjects were white and Finnish in origin. They underwent scanning in an MR 
imaging study of healthy humans with normal scanning results and no sign of carotid stenosis 
173, 482. 
 
A control population was chosen also for serial neuropsychological assessment, and their 
results were used as reference values in the study III. The group consisted of strictly healthy 
volunteers who were recruited by word of mouth. Half of them were a part of the 
aforementioned larger control population set undergoing MR imaging. The control persons 
were selected by age, sex, education, and social class. After sorting the patients by the 
respective criteria, we selected a matching control person for every second surgical patient, 
ending up with 22 control persons. Controls were matched for age (± 5 years), sex, and 
education and/or social class classified with three-category scales 483 (Table 2).  
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Table 2 . Clinical profiles of the patients and controls at baseline (± SD) in Study III. 
 
      
      Patients   Controls 
  
 Age      65.3 (± 8.4)   67.0 (± 8.9) 
 Body mass index    26.4 (± 4.2)   25.5 (± 4.2) 
 Cerebrovascular events 
  Stroke      7 (16 %)     0 
  TIA     14 (33 %)     0 
  None     23 (51 %)   22 (100 %) 
 Gender (female/male)    16/28    9/13 
 Education (years)    9.6 (± 3.2)   10.2 (± 4.8) 
  Higher      5 (11 %)     4 (18 %) 
  Secondary    16 (36 %)     8 (36 %) 
  Basic     23 (52 %)   10 (45 %) 
 Social class 
  Non-manual    12 (27 %)     6 (27 %) 
  Skilled manual    20 (46 %)   11 (50 %) 
  Unskilled manual   12 (27 %)     5 (23 %) 
 Arterial hypertension    16 (70 %)     0 
 Coronary heart disease     9 (39 %)     0 
 Diabetes      8 (35 %)     0 
 Peripheral arterial disease    7 (30 %)     0 
___________________________________________________________________________ 
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4.3  Methods 
4.3.1   Imaging techniques 
MRI 
 
All MR images were acquired on a Siemens Magnetom Vision whole-body clinical scanner 
(Siemens Medical Systems) operating at 1.5 Tesla, with a standard head coil. All imaging 
studies were completed without complications. The first imaging (n = 45) was performed in 
the evening on the day before surgery, and the scanning was repeated 3 days (postoperative) 
(n = 42) and 100 days (chronic) (n = 37) after CEA. Control subjects (n = 45) for the diffusion 
MR study were imaged once. No adverse effects occurred during the scanning procedure. 
 
DWI was performed with a spin-echo echo-planar imaging sequence having a repetition time 
of 4000 ms, an echo time of 103 ms, and a gradient strength of 25 mT/m covering 19 five-
mm-thick slices (interslice gap 1.5 mm, field of view 230 x 230 mm2, and matrix size 96*128 
interpolated to 256*256). Diffusion was measured in three orthogonal directions (x, y, and z) 
with 2 b-values (b = 0 and b = 1000 s/mm2). 
 
In addition to axial DSC-MRI, conventional T2- and proton-density-weighted images were 
obtained. The first imaging was performed in the evening on the preoperative day, and it was 
repeated 3 days and 100 days after CEA.  
 
DSC-MRI was performed with a gradient-echo echo-planar imaging sequence with a 
repetition time of 1.2 ms, an echo time of 42.1 ms, flip angle 90°, and a gradient strength of 
25 mT/m covering five 5-mm-thick slices (interslice gap 1.5 mm, field of view 230 x 230 
mm2, and matrix size 128*128). The centermost slice was leveled with corpus callosum and 
anatomical landmarks to keep the slicing constant. The slices were imaged one per second a 
total of 60 times. After collection of 7 baseline images, gadopentetate dimeglumine (GD-
DTPA, Magnevist, Schering AG, 0.15 mmol/kg) was injected into the antecubital vein via an 
18-gauge catheter at a speed of 5 mL/s using an MR compatible power injector (Spectris, 
Medrad), followed by a 10 mL flush of saline. The DSC-MRI data was analyzed as described 
in detail previously 484.   
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Transcranial Doppler ultrasound 
For the transcranial Doppler ultrasound the patient was examined in supine position in a quiet 
room. The recordings were made from ipsilateral MCA through the transtemporal window. A 
commercially available equipment (Nicolet EME Pioneer TC 4040) was used, and the 2-MHz 
pulsed-wave transducer was held in position by an external device. The baseline assessment 
was done within a few hours before surgery, and the postoperative one prior to the second 
MR imaging three days after surgery. Cerebral vasomotor reactivity was determined 
ipsilaterally by means of a breath-holding index as described previously, as well as Gosling’s 
pulsatility index (p. 24).  Microembolic signals were recorded by insonating middle cerebral 
artery at 50 mm depth. The audible Doppler shift and transformed spectra were monitored on-
line for 45-60 minutes. High-intensity transients that fulfilled the criteria of international 
recommendations were interpreted as microembolism (MES): short unidirectional signals 
occurring within the blood flow spectrum together with the characteristic sound without 
association to any potentially artefactual event 485.
4.3.2   Imaging data analyses 
In each hemisphere, 11 distinct neuroanatomical structures were selected for the analysis  
(normal-appearing frontal, parietal, temporal, and occipital grey and white matter, and the 
watershed regions between the territories of middle cerebral artery and anterior and posterior 
cerebral artery (Fig. 7).   T2 images were used to identify the relevant anatomical structures. 
ROIs were subsequently drawn manually on the CBF maps and transferred to the equivalent 
maps of absolute CBV and MTT. For each ROI, the following parameters were recorded: the 
surface area (40-120 pixels), the mean, standard deviation (SD), and range of the given 
values. The ROIs were analyzed blindedly with a commercially available image analysis 
software (Alice, Hayden Image Processing Group, Perceptive Systems Inc.).  
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Figure 7.  All regions of interest superimposed on average apparent diffusion coefficient maps.  
A) the parietal grey (1) and white matter (2), B) the anterior watershed (3) and posterior watershed 
region (4), C) the frontal grey (5) and white matter (6), the thalamus (7), D) the temporal grey (8) and 
white  matter (9), the occipital grey (10) and white matter (11). 
 
 
 
Two observers independently and blindedly 
evaluated the baseline and postoperative MTT  
maps for presence of a perfusion deficit   
(Figure 8).  Digital subtraction angiographies  
were analyzed by NASCET criteria by one 
experienced neuroradiologist  (O.S.) blinded  
to the clinical data 426. 
 
               
                     Figure 8.  Large perfusion deficit   
               on MTT map  
4.3.3  Neuropsychological assessment 
The cognitive assessment was done on the day before CEA, 4 days after the operation (5.0 
days after baseline), and at approximately 100 days (mean 102), in the same quiet room at 
approximately the same daytime, by either of two certified neuropsychologists. The control 
population was examined thrice with the same timing. The same examiner was used for 
repeated evaluations, and all controls were examined by the same examiner at all stages. The 
comprehensive neuropsychological test battery was completed in the same order, using 
parallel forms of tests in a randomly crossed fashion when applicable.  
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The test battery was designed using validated tests 486. Language domain was assessed by The 
Boston Naming Test (BNT) as naming and recognition of common objects (60), and Word 
fluency with the letter and category naming with one-minute generation of words by a letter 
(WF-L) or by a category (WF-C). Verbal memory and learning were evaluated by Auditory 
Verbal Learning Test with 5 trials to learn 10-word lists, scoring both sum score of trials 
(AVLT-SUM) and delayed memory recall (AVLT-D) and immediate verbal memory with 
WAIS-R Digit Span forwards and backwards (W-VESP). Visual memory and learning by 
Rey Visual Learning Test scoring the sum of five trials as well as delayed recall (RVLT-
SUM, RVLT-D), and immediate visual memory was evaluated with Corsi Blocks visual span 
forwards and backwards (CB-VISP). Motor dexterity was evaluated with Purdue Pegboard, 
scoring performance of the hand contralateral to the stenosis (PP-CONTRA). Attention was 
assessed with Letter Cancellation Task (LCT) and Trail Making A (TMA). Executive 
functions were assessed with The Trail Making and Stroop tests, making use of the 
differences of performance times in Trail Making A and B (TMB-TMA) as well as the word 
and colour naming in Stroop test (STROOP-INT) divided by the time spent on the first task.  
Mood was evaluated with Beck Depression Inventory.   
 
The distributions of the raw scores were studied, and logarithmic transformation was applied 
to BNT and TMB-TMA, and square root transformation to STROOP-INT.  The individual 
raw scores were standardized into Z scores using the controls’ baseline performance as the 
norm for the mean and standard deviations, and inverted for the time-based tasks for the 
increase of score to consistently indicate improvement of performance and decrease 
worsening. Domain scores were derived as average Z scores of the subtests. Compound 
cognitive score (CCS) was calculated by summing up the individual z scores and dividing by 
the standard deviation (SD) of summed scores. Cognitive change scores were calculated by 
subtracting the baseline scores from the timely score, and then by subtracting the average 
learning effect of controls from this result and by dividing the result by the SD of the control 
group 487, 488. A worsening of more than one standard deviation of CCS was considered 
dysfunctional. 
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4.3.4  Laboratory analysis 
Free flowing blood samples were collected from antecubital vein closely prior to operation  at 
8-10 a.m. into polypropylene and siliconized glass tubes for determination of fibrinogen 
(Clauss), thrombin-antithrombin complex  (ELISA, Behring), prothrombin fragments PF 1 
and 2 (ELISA, Behring), tPA antigen (Biopool, TintELIZA) and activity (Biopool, 
chromogenic assay) and PAI-1 antigen (Biopool, TintELIZA) and activity (Biopool, one-
stage chromogenic assay). D-dimer was determined by ELISA assay (Asserachrom® D-Di, 
Diagnostica Stago, Asnieres Sur Seine, France).  Plasma was separated immediately, 
centrifuged and processed. Description of the procedure as well as plasma processing 
conditions and intra- and interindividual variabilities of our assays have been published 
previously 489. Plasma total homocysteine was measured using a standard competitive 
immunoassay method (Immulite® 2000) from plasma sample stored at -70C. Haemoglobin, 
hematocrit, and platelet count were obtained using an ordinary autoanalyzer. Serum 
cholesterol and triglycerides were assessed by immunochemical methods, and serum calcium 
photometrically. High-sensitivity CRP assays were made with a sandwich enzyme 
immunoassay (UC CRP ELISA, Eucardo Laboratory, San Diego, CA). 
 
4.3.5  Carotid endarterectomy 
 
All standard CEAs were performed by one experienced vascular surgeon (E.S.).  The operator 
systematically recorded the morphology of the plaque at the operation denoting the general 
appearance: smooth vs. ulcerated plaque, presence and degree of calcification, loose 
atheroma, and intraplaque haemorrhage.  
 
 
4.4  Statistical analyses 
         
Distributions of the variables were studied with Shapiro-Wilk W test. Interhemispheric and 
regional variation as well as comparison between asymptomatic and symptomatic patient 
groups were studied with repeated-measures analysis of variance or covariance using 
symptomaticity as the between-subjects variable. The variance homogeneity was studied 
using Box M test and sphericity evaluated with Greenhouse-Geisser  values 490.  Pairwise 
comparisons were made with Student’s t test, correcting for multiple comparison. The 2 test 
or Fisher’s exact test was applied to univariate dichotomous variables. Correlations were 
studied with Spearman’s rank correlation. The values are given as means and  95% 
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confidence intervals or standard deviations. A two-tailed value of p < 0.05 was considered 
significant. 
 
The levels of coagulation and fibrinolytic markers between the groups were compared with 
Mann Whitney U test and Kruskal-Wallis analysis of variance. 2 test was applied in case of 
frequencies of discrete variables. Analysis of covariance was used in comparison of 
hematocrit. Backward stepwise logistic regression was applied with a core set of the studied 
haematological variables with the status of symptomatic stenosis as the dependent variable. 
Hosmer and Lemeshow test was used in evaluation of goodness-of-fit. The values are given 
as medians and interquartile ranges or means and 95 % confidence intervals.  
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5.  RESULTS            
5.1  Changes in brain diffusion
 
All ADCav values are given in  10-3mm2/s. The ADCav values of ipsilateral and contralateral 
hemispheres at different time points, in various regions of brain, and in different subgroups 
are presented in the Table 3 . 
5.1.1  Patients with carotid stenosis 
 
At baseline, ADCav values of the WM and watershed regions in the lobes of the hemisphere 
ipsilateral to the CS were higher than those of the contralateral side (p < 0.001, two-way 
ANOVA). Such an asymmetry was not detected in GM (p = 0.2) or thalamus (p = 0.8) (Table 
3). The surface area of regions with leukoaraiosis was larger in the ipsilateral than in the 
contralateral hemisphere (p < 0.04, Student’s t test). The ADCav values of these regions were 
not different between hemispheres (0.95 ± 0.12 vs. 0.95 ± 0.11, p = 1.0, Student’s t test). 
 
At the postoperative and chronic stages, the ipsilateral hemispheric WM and watershed 
regions had resumed lower ADCav levels not significantly different from the contralateral 
hemisphere (postoperatively, WM: p = 0.5; watershed regions: p = 0.9; at the chronic stage, 
WM: p = 0.5, watershed regions: p = 0.4; ANOVA) (Table 3). 
 
The lobar WM ADCav values were consistently different from one another at the three stages 
in each hemisphere (Figure 9). At the preoperative stage, the frontal and occipital lobes 
displayed higher values than occipital and temporal (p < 0.05, Scheffé test). The symptomatic 
group did not differ from the asymptomatic in ADCav values (Table 3). In the cognitively 
studied subpopulation (III), the ADCav levels (10-3 mm2/s) displayed the same pattern, being 
higher in the normal-appearing WM ipsilateral to the stenosis in comparison with the 
contralateral hemisphere (0.69 vs. 0.66, p < 0.001), decreasing in successive measurements 
(0.69 – 0.66 – 0.66) with abolition of the interhemispheric difference. In GM or basal ganglia, 
there was no difference in baseline ADCav levels (0.91 vs. 0.90, p = 0.22 for GM; 0.77 vs. 
0.77, p = 0.80, for basal ganglia). The levels decreased slightly in GM (0.91 - 0.89 - 0.90, p = 
0.03) with no interhemispheric difference. Two patient scans revealed new DWI lesions 
compatible with a minor watershed stroke, and a haemorrhagic lesion probably caused by 
postoperative hyperperfusion.  
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Table 3.   ADCav values of the regions in the subgroups (values mean ± SD, 95 % confidence 
  interval, unit 10-3 mm2 s-1) 
   SYMPTOMATIC ASYMPTOMATIC 
GREY MATTER            (n = 22)               (n = 23) 
   Stenotic side  
            Preoperative 0.92 ± 0.03  (0.90-0.93) 0.90 ± 0.03  (0.89-0.92) 
            Postoperative 0.90 ± 0.03  (0.89-0.91) 0.89 ± 0.03  (0.88-0.90) 
            Chronic 0.90 ± 0.03  (0.89-0.92) 0.89 ± 0.03  (0.88-0.91) 
     Contralateral side 
           Preoperative 0.90 ± 0.03  (0.89-0.91) 0.90 ± 0.02  (0.87-0.90) 
           Postoperative 0.89 ± 0.03  (0.88-0.90) 0.88 ± 0.02  (0.87-0.90) 
           Chronic 0.90 ± 0.03  (0.89-0.91) 0.88 ± 0.02  (0.87-0.90) 
     Controls 0.90 ± 0.05  (0.88-0.91) 
WHITE MATTER 
     Stenotic side  
           Preoperative 0.69 ± 0.04  (0.68-0.71) 0.69 ± 0.04  (0.67-0.71) 
           Postoperative 0.68 ± 0.04  (0.66-0.70) 0.67 ± 0.04  (0.65-0.69) 
           Chronic 0.67 ± 0.04  (0.65-0.69) 0.66 ± 0.03  (0.64-0.68) 
     Contralateral side 
           Preoperative 0.65 ± 0.03  (0.63-0.76) 0.66 ± 0.04  (0.64-0.68) 
           Postoperative 0.67 ± 0.04  (0.65-0.68) 0.67 ± 0.04  (0.66-0.69) 
           Chronic 0.67 ± 0.04  (0.65-0.69) 0.67 ± 0.04  (0.65-0.69) 
     Controls 0.63 ± 0.02  (0.63-0.64) 
WATERSHED REGIONS 
     Stenotic side  
           Preoperative 0.74 ± 0.05  (0.72-0.76) 0.73 ± 0.05  (0.71-0.75) 
           Postoperative 0.70 ± 0.06  (0.67-0.73) 0.70 ± 0.04  (0.68-0.72) 
           Chronic 0.70 ± 0.06  (0.67-0.73) 0.68 ± 0.04  (0.66-0.70) 
     Contralateral side 
           Preoperative 0.70 ± 0.04  (0.69-0.72) 0.70 ± 0.05  (0.68-0.72) 
           Postoperative 0.69 ± 0.06  (0.67-0.72) 0.71 ± 0.06  (0.68-0.74) 
           Chronic 0.68 ± 0.06  (0.65-0.70) 0.71 ± 0.06  (0.68-0.74) 
     Controls 0.65 ± 0.04  (0.64-0.66) 
THALAMUS 
    Stenotic side  
           Preoperative 0.77 ± 0.06  (0.74-0.79) 0.75 ± 0.06  (0.72-0.77) 
           Postoperative 0.78 ± 0.07  (0.75-0.81) 0.76 ± 0.06  (0.73-0.78) 
           Chronic 0.77 ± 0.06  (0.74-0.80) 0.74 ± 0.06  (0.71-0.77) 
    Contralateral side 
           Preoperative 0.77 ± 0.06  (0.74-0.80) 0.76 ± 0.07  (0.73-0.79) 
           Postoperative 0.76 ± 0.06  (0.73-0.79) 0.75 ± 0.06  (0.72-0.78) 
           Chronic 0.78 ± 0.09  (0.73-0.82) 0.73 ± 0.05  (0.71-0.76)  
     Controls 0.74 ± 0.04  (0.73-0.75) 
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Figure 9. Lobular mean white matter average apparent diffusion coefficient (ADCav) values (with 95% 
CI) of ipsilateral and contralateral sides compared with lobular white matter ADCav values of healthy 
control subjects. *) p = 0.001 (two-way analysis of variance, main effect, in comparison with the 
control population).  
 
 
Figure 10. ADCav levels (+ 95% CI) in white matter at the three stages in comparison with values of 
healthy population. IPSI = ipsilateral hemisphere; CONTRA = contralateral hemisphere; CONTROL 
= healthy population; BASE = baseline, preoperative stage; POSTOP = postoperative stage; 
CHRONIC = chronic stage.  
*) p < 0.001 (paired t test), **) p < 0.01, two-way repeated measures ANOVA 
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Watershed regions: 
  
 
  MTT            CBV             CBF 
 
 
 
 
White matter: 
 
  MTT            CBV             CBF 
 
 
 
Grey matter: 
 
  MTT            CBV             CBF 
Figure 11. Interhemispheric ratios for perfusion parameters in asymptomatic (open box) and 
symptomatic (hatched box) patients (box: SEM; whiskers: 95% CI). *P < 0.05, repeated-measures 
ANOVA.  
MTT = mean transit time; CBV = cerebral blood volume; and CBF = cerebral blood flow 
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5.1.2  Patients vs. controls
 
Preoperative ADCav values in WM and watershed regions ipsilateral as well as contralateral to 
CS were significantly higher in patients than in the control population (p < 0.001, two-way 
ANOVA), whereas no difference was detected in GM or thalamic level. Despite the higher 
ADCav level, the relative lobar differences in the WM of patients were identical to those in 
controls (Figure 9). Anterior watershed regions had higher ADCav values than posterior, on 
ipsilateral side (0.76 ± 0.05 vs. 0.71 ± 0.07; p < 0.001, one-way ANOVA), as well as on 
contralateral side (0.73 ± 0.05 vs. 0.67 ± 0.06; p < 0.001, one-way ANOVA), and in controls 
(0.66 ± 0.04 vs. 0.64 ± 0.04; p < 0.01, one-way ANOVA). In the course of time at the 
postoperative stage, the ADCav values had undergone a considerable decrease but remained 
significantly higher among patients than in controls for ipsilateral and contralateral WM and 
watershed regions (p < 0.001,  two-way ANOVA) (Figure 10). 
5.2  Changes in brain perfusion 
5.2.1 Interhemispheric, within-group differences
In the symptomatic CS group, the preoperative ipsilateral hemispheric MTT values were 
intraindividually higher than contralateral in WM and watershed regions (p < 0.001 for each, 
paired t-test), and marginally in GM (p = 0.05, paired t-test), but not in the asymptomatic 
group (Table 4). Correspondingly, the preoperative ipsilateral CBF values were lower in WM 
and watershed regions (p < 0.001 for each), and marginally in GM (p = 0.05, paired t-test) in 
the symptomatic group only. There were no differences in the asymptomatic CS group, 
notwithstanding the preoperative CBF values in GM, where the ipsilateral value was lower 
also in the asymptomatic group (p < 0.05).  In CBV values, there were no significant 
interhemispheric differences in either group at any stage (Fig. 11). The evolution of the 
interhemispheric ratios is depicted in Figure 11, showing the abolition of interhemispheric 
asymmetry by CEA and the significance of group 	
time interaction. In watershed regions, 
there was no difference between the anterior and posterior territories. 
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Table 4. Quantitative perfusion parameters at different timepoints with 95% confidence    
               intervals (preop: baseline, postop: 3 days after CEA; chronic:  3 months after    
               CEA).  P value is for two-way analysis of variance (group 	 time) 
 
 
MTT (s)             IPSILATERAL              CONTRALATERAL 
   symptomatic asymptomatic   P      symptomatic     asymptomatic         P  
 
 
GREY MATTER  
 preop  4.8 (4.3-5-3) 4.3 (3.6-5.0)  4.2 (3.8-4.7) 4.1 (3.5-4.7)  
 postop  4.4 (4.0-4.8) 3.9 (3.4-4.4)  4.4 (4.0-4.8) 3.8 (3.3-4.2) 
 chronic  4.0 (3.6-4.4) 4.3 (3.8-4.8)      0.05 3.9 (3.6-4.2) 4.3 (3.7-4.8) 0.04
WHITE MATTER 
 preop  6.5 (5.7-7.2) 5.6 (4.9-6.2)  5.1 (4.6-5.5) 5.3 (4.6-5.9) 
 postop  5.5 (4.9-6.1) 4.5 (4.0-5.0)  5.0 (4.6-5.5) 4.4 (3.9-4.8) 
 chronic  4.8 (4.3-5.3) 5.2 (4.7-5.8)    <0.001 4.6 (4.2-4.9) 5.2 (4.7-5.8)     0.004 
WATERSHED  
 preop  6.7 (5.9-7.4) 5.4 (4.8-6.1)  5.2 (4.7-5.7) 5.1 (4.5-5.6) 
 postop  5.6 (5.0-6.2) 4.5 (4.1-4.9)  5.0 (4.6-5.4) 4.4  (4.0-4.8) 
 chronic  5.0 (4.5-5.5) 5.0 (4.5-5.5)      0.02 4.6 (4.2-4.9) 5.2 (4.7-5.8) 0.01
CBV (mL/100 g)            IPSILATERAL              CONTRALATERAL 
   symptomatic asymptomatic   P      symptomatic     asymptomatic         P  
    
 
GREY MATTER  
 preop  4.6 (4.1-5-1) 4.6 (4.0-5.2)  4.6 (4.1-5.1) 4.6 (4.1-5.1)  
 postop  4.7 (4.4-5.1) 4.5 (4.0-5.0)  5.0 (4.6-5.3) 4.3 (3.9-4.7) 
 chronic  4.3 (3.8-4.8) 4.6 (4.2-5.0)      0.37 4.3 (3.9-4.6) 4.6 (4.2-5.1) 0.03
WHITE MATTER 
 preop  1.9 (1.6-2.1) 1.9 (1.6-2.2)  1.8 (1.6-2.0) 1.9 (1.6-2.1) 
 postop  1.8 (1.5-2.1) 1.7 (1.5-1.9)  1.8 (1.5-2.1) 1.6 (1.4-1.8) 
 chronic  1.6 (1.4-1.8) 1.7 (1.5-2.0)      0.60 1.7 (1.4-1.9) 1.7 (1.5-2.0)      0.41 
WATERSHED  
 preop  1.9 (1.6-2.2) 2.0 (1.8-2.3)  1.9 (1.6-2.1) 2.0 (1.7-2.3) 
 postop  1.8 (1.5-2.1) 1.8 (1.6-2.1)  1.8 (1.5-2.0) 1.8 (1.6-2.1) 
 chronic  1.7 (1.4-1.9) 1.8 (1.5-2.0)      0.99 1.7 (1.4-2.0) 1.8 (1.6-2.1) 0.99
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5.2.2  Between-groups differences 
 
The longer ipsilateral MTT in symptomatic CS patients before CEA, most pronounced in 
watershed regions and WM, improved in subsequent measurements, whereas in the 
asymptomatic group the improvement was marginal or transient (Table 4). In CBF, there was 
a trend for slightly lower preoperative values in the symptomatic group, and CBV levels 
remained essentially homogeneous.  None of the parameters showed significant groupwise 
differences after correction for multiple comparison. The p values in the study of the two-way 
interaction (group 	
 time) for each hemisphere are shown in the table 4. Results of between-
group analyses were not altered by having blood viscosity or degree of stenosis as covariates.   
 
Altogether 14 patients had a visible perfusion deficit in the ipsilateral carotid territory, with a 
perfect interobserver agreement ( = 1.0). Of the patients with a visualized hypoperfusion, 12 
were in the symptomatic group (p = 0.003, Fisher’s test). In the population with a visualized 
deficit, the mean MTT values for ipsilateral GM was 5.5 s (4.9 - 6.2 s, 95% CI), for WM 7.5 
(6.7 - 8.3 s), and watershed regions  7.2 (6.2 - 8.2) s. The respective values for the 
subpopulation without a deficit were 4.1 s (3.7 - 4.6 s ; p = 0.001), 5.4 s (4.9 - 6.0 s; p < 
0.0001), and 5.5 s (5.0 - 6.1 s; p = 0.002, t test). The interhemispheric MTT ratio was in 
visually hypoperfused subjects 1.28 (1.13 - 1.42) for GM, 1.46 (1.32 - 1.60) for WM, and 
1.39 (1.21 -1.56) for watershed regions. In subjects without deficit, the respective values were 
1.02 (0.98 - 1.06) s, 1.06 (1.01 - 1.11) s, and 1.09 (1.04 - 1.15) (p < 0.0001 for all 
comparisons, t test). The patients with a visible deficit represented higher grades of stenosis 
[85% (81 - 90%) vs. 76% (73 - 79%), p = 0.001, t test]. The lowest degree of stenosis with a 
visually detected perfusion deficit was 71 % (2 subjects). In the postoperative maps, no 
hypoperfusion was seen.  
 
In the subpopulation undergoing cognitive studies, the  preoperative MTT values were higher 
in the WM (6.0 s vs. 5.2, p < 0.001, t test) as well as in the GM (4.5 s vs. 4.2, p < 0.01, t test) 
ipsilateral to the stenosis. The difference was more pronounced in the symptomatic group, in 
which the WM MTT was longer than in the asymptomatic group (6.6 vs. 5.4, p = 0.02, t test).  
After CEA, the MTT shortened with disappearance of the within-subject interhemispheric 
difference (p < 0.02, ANOVA). In the cognitive substudy, there were 10 patients with a 
visible perfusion deficit in the ipsilateral carotid territory in MTT map, and 8 of these were 
symptomatic (p < 0.01, Fisher’s test). The observed deficits covered the arterial territory of 
the MCA (in two patients also ACA).  
 
  
   
  
   
  
 
68  
The ipsilateral PI was initially significantly lower in the symptomatic subjects, undergoing a 
similar pattern of improvement with no significant postoperative difference (Figure 12). The 
change in PI after CEA correlated with the improvement of the interhemispheric ratios of 
perfusion parameters. The association was significant for all parameters in WM (MTT, R = -
0.64, p < 0.0001; CBF, R = 0.42, p = 0.01; CBV, R = -0.46,  p = 0.006) and for two 
parameters in watershed regions  (MTT, R = -0.55, p = < 0.001; CBF, R = 0.46, p < 0.01; 
CBV, R = -0.10, p = 0.59), but not in GM  (highest in MTT, R = -0.29, p = 0.09, Spearman 
rank correlation). 
 
 
 
Figure 12. Ipsilateral findings on TCD measurement in asymptomatic (open box) and symptomatic 
(hatched  box) patients (box: standard error of mean; whiskers: 95% confidence interval). 
*) P < 0.05, t test.
 
 
The breath-holding index was comparable in the two groups at baseline, but only the 
symptomatic group improved postoperatively (group 	
 time interaction,  p = 0.02, ANOVA)  
(Figure 12).  The postoperative change in BHI was associated with improvement in  
interhemispheric ratios in MTT (WM, R = -0.53, p = 0.001; watershed regions, R = -0.34, p = 
0.04, GM, R = -0.34, p = 0.04), and in CBV, for WM (WM, R = -0.48, p < 0.005). 
Improvement of CBF was positively associated with change in BHI only in watershed regions 
(R = .46, p < 0.01). 
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5.3. Cognitive changes 
The baseline cognitive performance tended to be lower in patients in most domains, with no 
difference between asymptomatic and symptomatic groups (Table 5). The overall cognition 
was lower in subjects with higher degrees of leukoaraiosis as measured by both 
periventricular and disseminated WM hyperintensities (p = 0.02, group effect, repeated-
measures ANOVA). However, the degree of leukoaraiosis did not affect the cognitive change 
scores, and in repeated-measures ANOVA, there was no significant difference in the overall 
course (time 	 domain 	 dichotomized WMH effect). The patients were slightly more 
depressed than controls at all stages (average Beck scores 4.6 -4.8 vs. 1.6-2.2, p = 0.01).  
 
Table 5. Neuropsychological performance of the patients in SD units at baseline (controls = 0.00). 
 
 
 symptomatic      asymptomatic    P        P (controls) 
 
 
   Language  -0.17 -0.29   .58 .24 
   WF-L    -0.44     -0.71    .37       .03* 
   WF-C     0.04     -0.03    .83       .98 
   BNT    -0.10     -0.12    .92       .66
 
   Verbal memory     -0.39     -0.46    .81       .07 
   AVLT-SUM   -0.61     -0.63    .97       .07 
   AVLT-D    0.02     -0.24    .38       .68 
   W-VESP   -0.57     -0.49    .78       .03* 
 
   Visual memory     -0.45    -0.51    .86       .07 
   RVLT-SUM   -0.43    -0.45    .94       .12 
   RVLT-D   -0.35    -0.52    .68       .18 
   CB-VISP   -0.56    -0.55    .90       .03* 
 
   Motor dexterity PP-CONTRA   -0.32    -0.67    .28       .08 
 
   Attention      -0.33    -0.55    .59       .16 
   LCT    -0.57    -0.75    .76       .14 
   TMA    -0.28    -0.49    .60       .24  
 
   Executive functions     -0.66    -0.55    .82       .10 
   TMB-TMA   -0.77    -0.31    .45       .21 
   STROOP-INT   -0.13    -0.07    .87       .75 
   Compound cognitive score (CCS)   -0.70    -0.92    .64       .02* 
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__________________________________________________________________________
BNT=Boston Naming Test; WF-L= Word Fluency, Letter; WF-C=Word Fluency, Category;   
RVLT-SUM = Rey Visual Learning Test, sum of attempts; RVLT-D= Rey Visual Learning Test, Delayed 
Recall; AVLT-SUM= Auditory Verbal Learning Test, Sum of attempts; AVLT-D= Auditory Verbal Learning 
Test, Delayed recall; CB-VISP= Corsi Blocks, Visual Span; W-VESP= WAIS Verbal Digit Span;  
WR-SIMIL= WAIS-R Similarities, Incidental learning; PP-SUM= Purdue Pegboard, sum of hand scores;  
LCT= Letter Cancellation Test; TMB-TMA= difference of Trail Making A and Trail Making B time;  
STROOP-INT= Stroop Interference, difference of colours/words time; CCS= Compound Cognitive Score  
 
P: P value for comparison of performance of asymptomatic and symptomatic patients (uncorrected) 
P (controls) : P value for comparison of patients vs. controls (uncorrected) 
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Figure 13. Groupwise cognitive scores at the three timepoints [controls vs. patients, p < .01 for group 
effect, repeated-measures ANOVA].  asymptomatic stenosis; 	 symptomatic stenosis; 
 controls. 
 
The overall cognitive performance (compound cognitive score) improved equally in controls 
and in patients (p = 0.44, repeated-measures ANOVA, times 	 group effect) (Figure 13). In 
univariate analysis, the standardized change score was 0.16 SD lower in patients at the 
postoperative stage (p = 0.53), and 0.04 SD lower at the chronic stage (p = 0.91). The 
cognitive change scores did not correlate with the ADC or MTT changes at postoperative 
stage, but a weak inverse correlation to MTT was seen at the chronic stage (for GM, R = -
0.35, p = 0.03; for WM, R = -0.34, p = 0.04), the best domain being executive functions (R = 
-0.43, p < 0.01). Patients with a visible perfusion deficit at baseline tended to improve more in 
successive assessments (p < 0.04, repeated measures ANOVA) (Figure 14). Controlling for 
age or mood did not alter the findings. Correspondingly, in univariate analysis the cognitive 
change score of patients with an initial perfusion deficit was higher (postoperatively + 0.43 
SD vs. + 0.10 SD, p = 0.11; at the chronic stage + 1.13 SD vs. + 0.48 SD, p = 0.01). The 
improvement was marked in the domain of executive functions (postoperative  + 1.46 vs + 
0.70, p = .08; chronic + 1.81 vs + 0.74, p = 0.04), and a trend was seen in visual memory and 
language.  
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Figure 14. Cognitive scores in patients with a baseline perfusion deficit vs. patients without a visible 
deficit (p < 0.05, time 	 group interaction, repeated-measures ANOVA) 	  initial perfusion deficit;  
no perfusion deficit. [p < 0.01 for group effect, repeated-measures ANOVA]. 
 
 
On an individual level, there were 9 patients with a postoperative impairment of the 
compound cognitive score of one SD or more, and one patient with that of 2 SD. In the 
control group, 4 subjects had a total performance impaired by 1 SD or more, and none over 2 
SD. At the chronic stage, 5 patients were impaired by 1 SD, one of these as a result of a 
sizable frontal haemorrhage and one because of another unrelated emergent disease, and in 
the control group, none were impaired by 1 SD. The most sensitive domains to postoperative 
impairment were attention, motor dexterity, and verbal memory. In attentional tasks, 21 
patients (48 %) vs. 4 control persons (18 %) had an impairment over 1 SD (p = 0.03), the only 
difference reaching statistical significance, and in two patients the impairment exceeded 2 SD. 
In motor dexterity, 14 patients and 4 control persons had a postoperative impairment over 1 
SD (p = 0.38), exceeding 2 SD in one patient.  Notably, the two patients with new DWI 
lesions at the postoperative imaging showed no cognitive decline.
  
   
  
   
  
 
73  
5.4  Change in blood coagulation, fibrinolysis, and haemorheology 
5.4.1 General clinical and coagulation and fibrinolysis-associated variables 
 
The demography and risk factor profiles of the groups are given in Table 1 (p. 52), and the 
general laboratory and blood count variables in Table 6.  Age was positively correlated to D-
dimer (R = 0.32, p < 0.01), plasma homocysteine (R = 0.29, p < 0.01), erythrocyte 
sedimentation rate (R = 0.28, p < 0.01), fibrinogen  (R = 0.22, p = 0.04), and tPA activity (R = 
0.24, p = 0.02). Body mass index correlated strongly with PAI-1 antigen (R = 0.60 , p < 
0.001), PAI-1 activity (R = 0.59, p < 0.001), and tPA antigen (R = 0.50, p < 0.001), and 
inversely with tPA activity (R = -0.59, p < 0.001). Smoking habits were unrelated to 
coagulation and fibrinolysis-associated variables, and so was the type of the vascular event 
(stroke or transient ischemic attack). An estimate for viscosity, calculated from its principal 
determinants was higher in the symptomatic patients (Table 6) 319. Median high-sensitivity 
CRP levels were not different between the asymptomatic, symptomatic, and the symptomatic 
plaque groups (3.8 mg/L, 5.4 mg/L, 3.7 mg/L, p = 0.34). 
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Table 6.  Laboratory variables and microembolic signals (MES) of asymptomatic and symptomatic 
subgroups. Numbers  are given as means ± 95 % confidence intervals, and p values for a three-way 
comparison (Kruskal-Wallis analysis of variance, if not otherwise indicated) 
 
 
 ASYMPTOMATIC   SYMPTOMATIC,    SYMPTOMATIC,  
          OTHER          PLAQUE  
         (n = 18)           (n = 20)      (n = 54)  
________________________________________________________________________________ 
     
ESR (mm/h)    23 (12-34)     21 (15-26)   21 (17-24)               0.88 
Haemoglobin (g/L)        137 (130-144)            138 (132-144)   140 (138-143)         0.39 
Hematocrit (%)                     39.0 (37.5-40.8)         40.8 (39.2-42.5)   42.0 (41.1-42.9)        0.04*) 
Platelets (E9/L)    246 (214-278)            265 (238-298)   246 (227-266)         0.32 
Creatinine (mol/L)    96 (83-109)                92 (83-100)   92 (87-96)               0.93 
Calcium (mmol/L)    2.33 (2.24-2.41)         2.32 (2.29-2.36)   2.32 (2.30-2.34)      0.58 
Homocysteine (mol/L)    10.0 (8.0-11.9)           10.9 (9.0-12.8)   11.5 (10.2-12.8)      0.34 
Cholesterol (mmol/L)    5.2 (4.8-5.7)               5.5 (5.1-6.0)   5.5 (5.2-5.9)            0.51 
      LDL cholesterol    3.0 (2.6-3.5)               3.3 (2.8-3.8)   3.4 (3.1-3.7)            0.38 
      HDL cholesterol    1.5 (1.2-1.7)     1.3 (1.0-1.5)   1.3 (1.2-1.4)            0.22 
Triglycerides (mmol/L)    1.58 (1.25-1.91)         2.13 (1.53-2.72)   1.85 (1.49-2.21)      0.55 
Glucose (mmol/L)    6.1 (5.0-7.3)               6.4 (5.2-7.6)         6.1 (5.4-6.8)  0.98 
Calculated viscosity    0.23 (0.19-0.27)         0.27 (0.23-0.31)   0.29 (0.27-0.31)       0.04*) 
  [Fibr x (Hct)3]      
     
MES (/hour), all     1 (0-2)      4 (0-8)    6 (2-9) 0.15 
  (without 
anticoagulation)       4 (0-9)    7 (2-12)                0.14 
________________________________________________________________________________ 
(*)Analysis of covariance, adjusted for gender)    
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5.4.2  Comparison between symptomatic and asymptomatic patients 
 
The measured markers of coagulation and fibrinolysis showed no statistically significant 
difference in three-way univariate comparison, although tPA antigen values in symptomatic 
group tended to be higher (Table 7), and there was a trend for a higher MES count, 
particularly in cases of symptomatic plaques in comparison with the rest of the patients (p = 
0.07, Mann-Whitney U test). Uncorrected comparison between asymptomatic and ipsilaterally 
symptomatic CS reached significance for Hct and tPA antigen (p < 0.01 and < 0.05, 
respectively, Table 7). No significant correlation was found between MES counts and the 
measured markers in any subsets, nor did the markers correlate with the time elapsed since 
onset of symptoms. 
 
Table 7. Coagulation- and fibrinolysis-related laboratory values in asymptomatic and symptomatic 
subgroups; medians with interquartile ranges (w/a: patients without anticoagulation). 
 
 
 ASYMPTOMATIC   SYMPTOMATIC, SYMPTOMATIC P VALUE 
         OTHER      PLAQUE  
 (n = 18)        (n = 20)     (n = 54; w/a 35)   
________________________________________________________________________________
     
Fibrinogen 3.9 (2.9-4.8) 4.0 (3.4-4.6) 4.0 (3.2-4.5)          0.94 
        (w/a)  4.0 (3.4-4.6) 3.6 (2.7-4.4)          0.79 
tPA activity 0.6 (0.2-1.0) 0.7 (0.3-1.1) 0.6 (0.3-1.0)          0.27 
        (w/a)  0.7 (0.4-1.1) 0.5 (0.3-0.9)          0.14 
tPA antigen 7.0 (4.1-9.6) 7.8 (3.8-14.9) 8.9 (7.3-10.7)           0.12 
        (w/a)  7.8 (6.3-10.7) 8.6 (7.4-10.7)           0.07 
PAI-1 activity 7.0 (4.5-16.8) 8.3 (3.9-14.4) 10.1 (6.7-14.1)       0.56 
        (w/a)  8.3 (3.9-14.4)            10.5 (6.3-14.7)    0.09 
PAI-1 antigen 15.6 (6.4-25.9) 12.9 (8.2-20.0) 15.7 (11.1-19.7)     0.98 
        (w/a)  12.9 (4.7.9-22.2) 14.8 (10.6-19.5)     0.96 
D-dimer 0.5 (0.4-0.9) 0.4 (0.3-0.8) 0.4 (0.3-0.6)     0.64 
        (w/a)  0.5 (0.3-0.8) 0.5 (0.4-0.8)     0.89 
thrombin-
antithrombin 4.0 (2.5-11.8) 4.6 (2.6-10.4) 2.2 (1.8-4.1) 0.006 
        (w/a)  5.8 (2.7-10.4) 2.6 (1.9-4.9) 0.05 
PF 1 and 2 1.2 (0.8-2.1) 1.0 (0.8-1.5) 0.7 (0.4-1.2)        0.06 
        (w/a)  1.1 (0.9-1.5) 1.1 (0.7-1.3)           0.64 
__________________________________________________________________________ 
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In backward stepwise logistic regression analysis taking into account all the studied variables 
pertaining to coagulation and fibrinolysis as independent and the symptomatic plaque as the 
dependent variable, tPA antigen remained in the model as the only significant predictor (OR 
1.27, 95% CI 1.04 -1.55, p = 0.02). When hematocrit was included in the variables, it 
remained in the model (OR 1.22, 95% CI 1.05 -1.45, p = 0.04) together with tPA antigen (OR 
1.31, 95% CI 1.03 -1.66) and PF 1 and 2 (OR 0.64, 95% CI 0.46 -0.89).  
 
5.4.3  Effect of medication 
 
Only four patients had neither antiplatelet nor anticoagulant treatment. Anticoagulation with 
warfarin (n = 22) had expectedly a powerful lowering effect on thrombin-antithrombin 
complex (3.4 vs. 5.9, p < 0.01), PF 1 and 2 (1.2 vs. 1.7, p < 0.01) and D-dimer (0.34 vs. 0.50, 
p < 0.01, Mann-Whitney U test), associated with lower prothrombin time (27 vs. 117, p << 
0.01) and a fraction higher activated partial thromboplastin time (43.5 vs. 31.5, p < 0.01).  
Fibrinolytic marker levels and platelet counts were uniform in the anticoagulated and non-
anticoagulated groups.  Statin users had apart from significantly lower total and LDL 
cholesterol levels also lower ESR (18 vs. 24, p = 0.02) and a trend for fewer MES (3.1 vs. 5.3, 
p = 0.10). There were no differences in the measured variables between statin or ACE 
inhibitor users and non-users.  
5.4.4  Degree of carotid stenosis
Degree of stenosis had an overall trend for negative correlation to variables  PF 1 and 2, D-
dimer, and tPA activity. The trend was strongest in ipsilateral symptomatic patients without 
anticoagulation (n = 33; for PF 1 and 2, R = -0.32, p = 0.02 ; for D-dimer, R = -0.41 , p = 
0.02;  for thrombin-antithrombin complex, R = -0.20, p = 0.15; for tPA activity R = -0.30, p = 
0.03, Spearman Rank correlation), and was lacking in asymptomatic CS. Correspondingly, an 
overall trend for positive correlation was seen in tPA antigen, PAI-1 antigen and activity, and 
the phenomenon was most pronounced in ipsilateral symptomatic CS patients (for tPA 
antigen, R = 0.58, p < 0.01; for PAI-1 antigen, R = 0.49, p = 0.03, and PAI-1 activity, R = 
0.33, p = 0.15). Fibrinogen had no association with the degree of stenosis, whereas hematocrit 
was positively correlated to it in both asymptomatic and symptomatic groups (R = 0.32, p < 
0.01 for total population) 
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5.4.5  Plaque characteristics 
 
With smooth plaques the MES counts tended to be lower and with ulcerated plaques higher  
(for both, 3.7 vs. 5.2, p = 0.03, Mann-Whitney U test) (Table 8). Intraplaque haemorrhage 
tended to associate with higher degree of stenosis (79.6 vs. 75.5 %), reduced platelet count 
(238 vs. 261  E9/L) and elevated hematocrit (41.9 % vs. 40.3 %, p < 0.05 for all, Mann-
Whitney U test) but not with the variables of coagulation and fibrinolysis (data not shown). 
Anticoagulated  ipsilaterally symptomatic patients  had fewer haemorrhagic plaques than non-
anticoagulated  (9 (42 %)  vs. 23 (70 %) , p = 0.05,  2 test). 
Table 8. Macroscopic characteristics of the plaque at surgery 
 ASYMPTOMATIC    
 
SYMPTOMATIC,     SYMPTOMATIC   
         OTHER               PLAQUE 
            (n=18)         (n=20)           (n=54) 
PLAQUE    
_______________________________________________________________________________ 
smooth         13 (72 %)      15 (75 %) 27 (53 %) *) 
ulcerated          5 (28 %)       6 (30 %) 29 (54 %) *) 
calcified        14 (78 %)      11 (55 %) 31 (57 %) 
loose atheroma          2 (11 %)       4 (20 %) 14 (26 %) 
haemorrhage          8 (44 %)       8 (40 %) 32 (59 %) 
________________________________________________________________________________ 
*) p < 0.05, 2 test    
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6. DISCUSSION  
 
6.1  Changes in brain diffusion
In the diffusion study, the ADCav values were found to be elevated in the WM and the 
watershed areas of the hemisphere ipsilateral to a high-grade CS; furthermore, removal of the 
stenosis brought the values promptly back to the same level as in the contralateral 
hemisphere. The finding was consistent in the asymptomatic and the symptomatic subgroups. 
Yet, the ADCav values of GM and thalamus displayed neither interhemispheric nor 
postoperative variation, and, despite the postoperative decline, the ADCav values of WM and 
watershed regions of patients remained higher than those of the controls regardless of the 
hemisphere or time point. Although the magnitude of the ADCav change was small, it was 
consistent enough both among the patients and between the different lobes of the brain as to 
make is statistically clearly significant, and thus chance variation remains an improbable 
explanation. 
 
Rise of ADC levels indicates less restriction to diffusivity in the tissue. Chronically increased 
diffusion implies a structural change which may be a form of permanent damage, such as 
chronic ischemic stroke or presumably LA. In case of tissue destruction, the ADC elevation 
can be assumed to be irreversible. The ADC elevation may be sensitive to a ‘subclinical’ level 
of change in tissue structure as shown in the normal-appearing WM patients with advanced 
WM lesions 171. A more informative way to characterize the structural change or damage  
change would be diffusion tensor imaging capable of producing multiple indices, especially, 
fractional anisotropy, which is inversely proportional to ADC levels 491. Several studies have 
confirmed the change in the normal-appearing WM in patients with WM lesions, and some of 
the studies have been able to show a correlation to the degree of cognitive dysfunction, 
mainly in the domain of executive functions 120, 492, 493. WM has appeared the most vulnerable 
in experimentally induced chronic hypoperfusion; moreover, human studies with DSC MRI 
and positron emission tomography have detected hypoperfusion in association with WM 
lesions, which is consistent with the notion of a low-grade perfusion deficit 378, 383, 484, 494, 495. 
Yet, it remains in question whether hypoperfusion is the cause or the effect in case of the WM 
lesions. In our study, the perfusion sequences revealed diminished perfusion ipsilateral to the 
stenosis in a considerable proportion of the patients, and so it is prudent to ask what kind of 
an effect the perfusion deficit would technically have on the ADCav values. Since the rate of 
perfusion is estimated to constitute a few percent of the ADCav values of the brain tissue, the 
expected consequence of a perfusion deficit per se would be a minor ipsilateral ADCav 
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decrease 180. As the ipsilateral ADCav values, to the contrary, were significantly higher than in 
controls, it is evident that other physiological mechanisms and consequences predominate 
over the short-term direct effect of reduced perfusion. What is more, also the contralateral 
ADCav values were higher in the patients than in controls, which underscores the pivotal 
differences between patient and control populations and probably reflects the patients’ greater 
propensity to WM changes in comparison to a population without cerebrovascular risk 
factors. 
  
Reversible elevations of the ADC may be encountered in vasogenic oedema, e.g. hypertensive 
encephalopathy, eclampsia, or posterior reversible encephalopathy syndrome 160, 167, 496, 497. In 
these cases, the permeability of the blood-brain barrier is altered, and intra- and extracellular 
water is redistributed so that excess water is found in the interstitium. When CS is sufficiently 
tight to cause relative hypoperfusion, the expected haemodynamic change would be vessel 
dilatation and an increase in cerebral blood volume (CBV). After CEA, the ipsilateral flow 
increases, and the blood volume would be expected to either decrease or remain unchanged 
498, 499. Perfusion would thus improve, which could induce a slight elevation of ADCav values. 
In our study, no significant alteration in CBV was detected at any of the three stages; 
however, it is possible that the magnitude of change needed to be reflected in ADC values is 
greater, and the sensitivity of the perfusion imaging methodology used in this study may be 
insufficient for detection of a minor difference. At any rate, the detected postoperative ADCav 
decrease is contrary to the change that would be expected solely on the basis of the altered 
perfusion. 
 
The contralateral hemisphere had unaltered diffusion after the operation, neither did the 
ADCav values of GM or thalamus change in either hemisphere. These entities are not only 
structurally different from WM but their inflow of blood has other sources: GM is supplied by 
leptomeningeal collaterals, and thalamus by vertebrobasilar circulation 500, 501. The lack of 
variation is concordant with the observation that the ADCav levels of GM and thalamus were 
equal in the patients and controls, in contrast to the differing values in WM.  
 
Both asymptomatic and symptomatic subgroups had uniform levels of ADCav values in the 
ipsilateral hemispheres, and their development was similar in the follow-up. The groups were 
homogeneous also in terms of the patient characteristics (age, risk factors, and degree of CS) 
at baseline. Thus, in this context, ADCav measurements did not distinguish the symptomatic 
from the asymptomatic or shed any light on the question why and how some patients with 
similar CS become symptomatic. In within-subject analysis, the anterior watershed regions 
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had higher ADCav values than the posterior watershed area at every time point. This supports 
the previous study and our own findings of the frontal lobes having the highest ADCav levels 
499. The impact of a stenosis in anterior circulation may have a propensity to accentuate the 
lobar differences, depending on the degree of subservience by anterior or posterior circulation 
and the effectiveness of collateralization. 
 
The overall finding of elevated preoperative ADCav values and their partial reversal by CEA, 
and the fact that they remained higher than in the normal controls even at the chronic stage, 
suggest that both reversible and irreversible components exist in the impact of a severe CS on 
the ipsilateral WM. The observed net decrease of ADCav supports the hypothesis of a 
corrective effect on cellular-level pathophysiological mechanisms, such as chronic ipsilateral 
relative ischaemia. The finding of a slightly larger volume of LA in the ipsilateral hemisphere 
may give some support to the notion of LA-inducing potential of CS, in accordance with a 
previous positron emission tomography study 495. 
6.2  Changes in brain perfusion 
The most sensitive parameter to the haemodynamic effect of CS in perfusion imaging was 
MTT, supporting previous findings 484, 502. MTT values improved not only in the hemisphere 
ipsilateral to the stenosis but also to some extent in the contralateral hemisphere, which 
contributed to the significance of the group 	
time interaction. The baseline MTT maps 
revealed a visually detectable perfusion deficit in over half of the symptomatic group, and the 
finding was significantly associated with symptomatic status. On the basis of these data, the 
threshold for visual detection of the perfusion deficit can be approximated as an MTT 
prolongation of more than 15-20 % on the affected side. The high prevalence of a chronic 
perfusion deficit in the symptomatic group needs to be kept in mind as a potential confounder 
in the setting of acute ischaemia, as it may erroneously be regarded as tissue-at-risk 503, 504. In 
such cases, more comprehensive vascular imaging is needed to differentiate the chronic form 
of hypoperfusion from the acutely emerged one.  
 
The variation of perfusion parameters from the acute to the chronic stage was negligible 
especially in the asymptomatic patients. This lack of effect in a considerable part of subjects 
may explain why little long-term change has been detected in previous studies 498, 499. Our 
findings also corroborate the greater haemodynamic impairment of WM in comparison to GM 
505. However, the watershed areas did not appear specifically vulnerable to lower perfusion 
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but resembled the rest of the chosen WM regions of interest, and no perfusion asymmetry was 
found between the anterior and posterior borderzones 499. Variation in CBV was lowest of all 
perfusion parameters, and not more than minute differences between the asymptomatic and 
symptomatic groups were seen. In principle, CBV parameter should not be sensitive to delay 
and dispersion of the bolus, but it seems unlikely to be a sensitive indicator of haemodynamic 
reserve 75, 341, 484, 502.  
 
TCD findings displayed little difference between asymptomatic and symptomatic groups in 
the preoperative reactivity, but the reactivity improved notably only in the symptomatic 
patients, suggesting some degree of preoperative haemodynamic compromise. In addition, the 
correlation between the attenuation of interhemispheric asymmetry of MR parameters and the  
improvement of BHI underlines the effect of CEA in symptomatic patients. Pulsatility index 
is proposed to reflect cerebrovascular impedance, and it is influenced by several properties of 
the vasculature as well as by cardiac function, and it has been applied as an indiscriminate 
index of vascular resistance 507.  It has been associated with symptomatic status, and it is 
known to improve after CEA, but its predictive value has been poor 75, 507, 508. CS decreases 
pulsatility index by reducing inflow, and retained pulsatility is thought to indicate lower 
impedance of collateral vessels. In our study, the preoperatively lower pulsatility index and 
the greater postoperative improvement of pulsatility in the symptomatic patients is in accord 
with more severe initial haemodynamic impairment and previous findings 507. However, since 
pulsatility index is an inaccurate measure of vascular resistance and it is affected by many 
confounding parameters, its value to a clinician in the context of CS is at least limited. At this 
stage, the clinical use or benefit of vasoreactivity testing is not established, either. To evaluate 
its predictive value among other predictors would require a large study population, and it 
could be beneficial to apply a more exact testing method than breath-holding. 
 
Overall, the perfusion results corroborate that within a homogeneous patient population with a 
unilateral high-grade carotid stenosis, the patients who develop symptoms have in general a 
poorer haemodynamic adaptation to the stenosis than the patients who remain asymptomatic. 
This tendency may be detected as an abnormal interhemispheric ratio of MTT in DSC MRI, 
which often produces a visible perfusion deficit in perfusion mapping. Consequently, the 
symptomatic patients also improve more clearly after CEA than the haemodynamically more 
stable asymptomatic patients whose long-term haemodynamic response was negligible in our 
study. The better haemodynamic adaptation may partly account for the lesser benefit from 
surgery in asymptomatic patients. 
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6.3. Cognitive changes 
6.3.1 Cognitive dysfunction  
Patient groups with risk factors and CS were consistently inferior in cognitive performance in 
comparison to a matched group without major risk factors. The long-term inferiority is not 
surprising, as cerebrovascular disease and cognitive impairment share several risk factors. 
Although previous cerebrovascular events could explain the difference especially in a 
symptomatic group of patients, considering the absence of major strokes and the low overall 
level of MR lesions in the symptomatic group as well as the homogeneous performance level 
in symptomatic and asymptomatic patients, the patient population seems to differ from the 
healthy controls irrespective of clinical vascular events. Still, an equal number of lacunar 
infarctions were detected in both patient groups; these are known to be one of the central 
mediators of cognitive decline, and here they may serve as markers of the underlying 
cerebrovascular disease along with the WM lesions 415.  Apart from minor strokes and WM 
lesions, the cognitive impairment in CS patients could be due to microembolization, regional 
hypoperfusion, or to other mechanisms. Further information on the mechanisms could have 
clinical implications and help define appropriate therapeutic interventions. 
      
The cognitive dysfunction after CEA has become a well documented finding during the last 
decade. In the publications the incidence of dysfunction has attained to or exceeded one-
fourth of patients 16, 18, 465, 468. Considering the primarily preventive nature of the intervention, 
complications would threaten its aims, and one should be aware of potential subtle cognitive 
effects, which might easily go unnoticed in the clinical practice and not be taken into account 
in complication rate assessments of CEA. However, it is to be borne in mind that the reported 
figures are relative and determined by the set criteria for dysfunction, and thus arbitrary, and 
not much is known about the long-term effects or the actual ‘real-life’ significance of the 
postoperative cognitive decline to the patients’ discharge from the hospital, their daily life, 
recovery, or well-being. Nevertheless, the occurrence of postoperative cognitive decline 
underlines the importance of identifying high-risk patients, whenever possible, and opting for 
prevention with appropriate operative and monitoring techniques.  
 
Our study revealed a noticeable postoperative dysfunction in a number of patients, using strict 
criteria for dysfunction, although the changes were not strongly reflected in group means. 
When criteria adopted by Heyer et al. were used, there were fewer patients with cognitive 
deficits than anticipated 16. The stricter criteria may be more appropriate for the limited 
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sample size, albeit that the risk of false positive findings becomes substantial, i.e. subjects are 
classified as having postoperative cognitive decline merely because of the intrinsic variability 
of the neuropsychological instrument, or the observed decline in test performance is not 
translated to any considerable disability in daily life. One of the many confounding elements 
in this setting is general anaesthesia, which decline is at times attributed to, but the recent 
results do not support its role 465. Some decline in our material may have been artefactual and 
due to the intrinsic variability of the instrument, e.g. because of suboptimal parallel test 
versions, as a transient decline was seen in control group as well (Figure 13). The decline was 
also a DWI-negative phenomenon, as in previous reports 17, 509. Furthermore, the subjects with 
new postoperative DWI lesions were not classified as having cognitive decline by their test 
performance. The insensitivity of the cognitive assessment to appearance of new DWI lesions 
can be interpreted as a reminder of the ‘non-localizable’ network functioning of the brain, 
expected to be more sensitive to disseminated microembolic loads over time, low-grade 
regional hypoperfusion, or widespread gradual changes, than punctate lesions.  
 
Finally, considering the generally good performance of the subjects at the three-month time 
point and the overall clinical impression, the transient cognitive effects could be interpreted as 
mild and not constituting a clinical problem in this patient group. However, questions on the 
importance of the finding cannot be answered within this study design but would require a 
larger study population, a different approach and a longer follow-up time; neither can 
predictors for postoperative decline be determined within this design. 
6.3.2  Cognitive improvement 
The overall cognitive improvement of the patients after CEA reflected a learning effect that 
was as good as in healthy peers regardless of the WM lesion severity.  The PWI result 
suggesting a greater cognitive improvement in patients with visible perfusion deficits tallies 
with recent reports of a greater cognitive improvement in patients with compromised cerebral 
vasoreactivity, two of them published after the completion of our study 478-480. According to 
previous PWI findings, these patients may represent mainly symptomatic subjects with poorer 
collaterals and exhausted physiological cerebrovascular autoregulatory buffer. Such a 
subgroup would be more prone to recurrent ischaemia or spells of inadequate oxygen supply 
as well as impaired clearance of microemboli 347, 351, 510. Poorer reserve capacity, on the other 
hand, could also increase surgical risks.    
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Preliminary domainwise analysis was possible with our comprehensive study battery, and the 
improvement was mainly based on better executive functioning. This finding is supported by 
the recent small study by Fukunaga et al. 479  Executive functions involve planning and goal 
setting, coordination of multiple tasks while storing information, set shifting between stimulus 
and response, and deployment of attentional resources; from the point of view of cognitive 
neuroscience, executive functions require large-scale network functioning of the brain and 
connectivity, essentially through fronto-subcortical circuits. On the basis of many studies, 
execution is postulated as the most sensitive cognitive domain to age-related connective 
integrity and white matter pathology 510, 511. This sensitivity obviously explains the high 
incidence of dysexecutive problems in cerebrovascular disease as well. 
  
The finding of cognitive improvement needs to be interpreted with caution; nevertheless, the 
prospect of improvement in the most hypoperfused individuals deserves further study with 
larger sample size, preferably with a more hemisphere-specific testing battery dimension. 
Furthermore, despite the predominance of symptomatic patients in the most hypoperfused 
group, notably two out of ten in our study were asymptomatic in this substudy. In principle, 
perfusion status could serve as an accessory criterion in selection of asymptomatic patients 
that might benefit from CEA, but evidence from controlled trials is needed. 
 
The cognitive score change was not directly correlated with the small but consistent and 
partially reversible elevation of ADC values detected in the diffusion study. However, should 
higher ADC levels indicate a step towards WM degeneration, this would provide a link with 
the long-term cognitive deterioration, which was outside the scope of the design of our study 
512. If the link exists, and WM degeneration is seen as a target for prevention of cognitive 
decline, CEA would provide a means of preventing cognitive deterioration in the long run 
also by protecting WM, not only by reducing the risk of stroke. 
 
6.4  Change in blood coagulation, fibrinolysis, and haemorheology 
The thrombogenic process in carotid occlusive disease involves blood and plaque properties 
as well as blood flow conditions. In this cross-sectional study, we chose to compare selected 
markers of coagulation and fibrinolysis, and the most general factors of viscosity, to see 
whether they appeared involved in the process transforming an asymptomatic high-grade 
carotid stenosis into a symptomatic one. Although the study design and the sample size does 
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not allow firm conclusions, the results support the association of both coagulation-fibrinolysis 
and haemorheology with generation of symptoms in advanced CS.  
Elevated viscosity estimate was associated with the symptomatic state, and it was notably due 
to increased hematocrit (Hct) levels, not to rise in fibrinogen (Table 6). Otherwise, the 
subpopulations had uniform risk factor profiles and demography, apart from the female 
predominance in the asymptomatic group, due to chance or gender-associated difference in 
plaque constitution, as well as the basic serology including lipid profile and homocysteine 
(Table 1) 513. Hct may have an impact as a significant contributor to local shear stress and von 
Willebrand factor-mediated formation of platelet thrombus, and the shear force and flow 
conditions have their effects on several mechanisms of thrombosis 514, 515. Unfavourable 
haemorheology may not only be a mediator of the initial injury to the vessel wall, giving 
impetus to atherogenesis, but also a risk factor for generation of symptoms through local 
shear, thrombus-forming effects on platelets, and greater risk of turbulence and stagnation of 
flow. CS could be an especially prone site, considering the high-shear and turbulent flow 
conditions in the carotid arteries in comparison with e.g. coronary arteries. Increased viscosity 
has been associated with enhanced stroke risk in prospective studies with synergistic effects 
with other risk factors as well as with carotid intima-media thickness, and elevated viscosity 
levels have been detected in acute stroke 322, 323, 516-518. However, rheological studies in acute 
stroke have detected elevations in fibrinogen rather than Hct, although some studies have 
documented increased Hct in presence of CS 322, 323, 517. In principle, haemorheological 
impairment could give rise to symptoms also through influence on cerebral perfusion in cases 
of less well-developed collateralization. Yet, the acute cerebrovascular event itself could be a 
confounding factor in symptomatic CS, as both acute-phase elevations and decreases have 
been described in patients with a recent thrombosis, in addition to elevated fibrinogen 517, 519, 
520. Our study lacked major infarctions, however, and the baseline levels did not correlate with 
the time elapsed since symptoms. Although no direct measurements of viscosity were made in 
this study, the results support the notion that the haemorheological aspect merits further 
consideration in future studies 521.  
 
Coagulation- and fibrinolysis-related variables showed little difference in univariate analysis, 
although the trend of higher tPA antigen together with the relatively low tPA activity implies 
reduced fibrinolytic capacity in the symptomatic group. In multivariate analysis, elevated tPA 
antigen levels seem to associate with the symptomatic plaque more clearly, in line with 
previous studies where elevated tPA antigen has appeared as a risk factor and a predictor of 
future vascular events 316, 522, 523.  A similar association has been reported in severe peripheral 
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arterial disease and thrombotic events in coronary heart disease, whereas PAI-1 has not 
consistently displayed an association despite its definite role in fibrinolysis 524-526. 
Involvement of the plasminogen system in activation of matrix metalloproteinases and thus 
eventually plaque instability and tissue remodeling may underlie its importance in this setting 
527. The finding suggests that elevated tPA antigen may be an indicator of endothelial 
dysfunction and plaque instability as well as reduced fibrinolytic capacity to counteract 
intraluminal thrombus formation also in advanced carotid disease, thus contributing to the 
generation of symptoms. An overall ‘thrombogenic profile’ with higher level of thrombin 
generation together with impaired fibrinolysis was not detected, suggesting that induction of 
symptoms by an intrinsically abnormal coagulation-fibrinolysis pattern is not common in this 
patient group, or it may have been modified before blood samples were collected. The low-
level PF 1 and 2, and thrombin-antithrombin complex are likely confounded not only with the 
active anticoagulant treatment in a major part of the most symptomatic patients but also the 
time elapsed since the symptomatic stage.  
 
The degree of stenosis revealed a positive association with fibrinolytic factors tPA antigen, 
PAI-1 antigen and activity especially in presence of an anticoagulant lowering the overall 
level of thrombin generation. Correspondingly, increasing stenosis was involved with 
decreasing levels of PF 1 and 2, D-dimer, thrombin-antithrombin complex, and tPA activity, 
and this phenomenon was evident without the interfering presence of anticoagulation. This 
supports involvement of the fibrinolytic system in the evolution of atherosclerotic disease into 
the symptomatic stage, especially as no association of tPA antigen and the grade of stenosis 
was detected in the asymptomatic group. The correlation between tPA antigen and the 
stenosis degree was highest in the anticoagulated, ipsilaterally symptomatic stenoses, 
probably explained by the selective attrition the most symptom-generating and unstable 
plaques in this subgroup, as their degree of stenosis was not higher per se. The expression of 
markers may also be affected by the flow and perfusion condition, which were found in the 
perfusion imaging substudy to be better in the asymptomatic patients.  
 
The macroscopic appearance of the symptomatic plaques with more frequent ulcerations and 
intraplaque haemorrhages was associated with clinical symptoms and MES counts but not 
with mediators of coagulation and fibrinolysis. This may reflect the importance of plaque 
ulceration as a nidus for thrombi even in absence of increased thrombogenic potential 301.  
The lack of association may also serve as a reminder of the systemic nature of the markers 
and disease, determined by the extent and nature of the overall burden of atherosclerosis 
rather than reflecting a local process. This may also explain why CRP levels did not 
differentiate the groups, which all displayed levels that generally indicate a high risk for 
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cardiovascular events. The initial approach of attempting to cross-correlate plaque processes 
related to inflammation and cell death to symptom-associated systemic factors did not 
produce any robust correlations withstanding the necessary corrections for multiple statistical 
comparisons. Notably, although the risk factor profiles and grade of stenosis were comparable 
between the subgroups, the overall atherosclerotic lesion burden was not known. The 
association of intraplaque haemorrhage with higher hematocrit and calculated viscosity may 
suggest the impact of higher shear on bleeding tendency and constitute a possible mechanism 
of symptom generation. 
6.5  Limitations of the studies 
The fundamental limitations of all substudies are the limited sample size and the relatively 
short follow-up time. The heavy imaging protocol and the comprehensive neuropsychological 
battery have made the substudies labour-intensive and curbed the recruitment numbers, which 
has brought on statistical limitations and precluded many subgroup analyses. Since the 
follow-up time was barely longer than three months after the baseline, little can be said about 
the actual long-term effects of CEA. 
 
The imaging studies involve some technical limitations. Firstly, analysis of the various 
regions of interest is challenging because of the potential contamination risk with 
neighbouring substance or cerebrospinal fluid,  especially in case of GM regions of interest. 
However, as especially ADCav values were within a very narrow range in this study (Table 3), 
the contamination seems unlikely, and the same applies in principle to the haemodynamic 
parameters. Secondly, perfusion imaging and its analysis has intrinsic limitations. Perfusion 
MRI has not become strictly quantitative, essentially because the basic assumptions 
concerning the underlying microvascular structure are simplified 189, 190.  Even if the values 
would be expected to be reasonably proportional to the actual blood flow measured, the 
premises of the calculation may lead to systematic errors. The fairly low resolution of the 
images enhances the risk of partial volume effects. These shortcomings could be partially 
improved by correction algorithms 528. In this study, the main focus was on comparison and 
relative values, and we refrained from using correction methods. Potentially greater and even 
crucial problem in the presence of a CS could be the absolute dependence on arterial input 
function, which is a prerequisite for quantification. Delay or dispersion in the bolus passage 
would inevitably introduce error. We selected an arterial input function from the contralateral 
hemisphere, using a feeding branch of the middle cerebral artery distal to the circle of Willis 
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for determination as close to the region of interest as reasonable, after the input of main 
collaterals, even at a somewhat greater risk of partial volume effects. Finally, one of the 
confounding factors is the variation in the fraction of cardiac output reaching the brain. In this 
material, the risk may not be substantial as major cardiac diseases were criteria for patient 
exclusion. 
In the study on cognitive functions, neuropsychological assessment as a sensitive tool with a 
considerable intrinsic variability may be especially prone to confounding elements in repeated 
testing in the surgical setting 487, 488.  Furthermore, in successive testing within a limited time 
frame, the subject’s performance will inevitably improve in a number of neuropsychological 
tasks by learning effect. To control for learning, we chose to compare the subjects to healthy 
peers examined within the same time frame. This group may, however, be suboptimal as the 
anxiety and motivational levels of healthy people differ from those of the patients. On the 
other hand, although their cognitive performance was better it was not as far superior as to be 
cut down by ceiling effect of the subtests, and being strictly healthy they assumedly provided 
a good measure for the natural learning curve which the patients would hardly be expected to 
surpass. The use of compound cognitive score may be criticized for bringing about bias and 
redundancy or loss of information since no tests are domain-specific. Still, compounding may 
serve to bring out underlying trends, in addition to the obvious advantage of lesser need for 
multiple comparison and corrections. In the present study, the restricted sample size does not 
allow for robust corrections nor a breakdown into hemisphere-specific analysis. 
 
The study on coagulation, fibrinolysis, and haemorheology has the most crucial limitations 
despite the largest sample size. Firstly, the selected study variables do not reflect the total 
haemostatic process but there are potential factors that have not been studied (e.g. platelet 
functions). Secondly, the timing of laboratory sample collection is hopelessly late, as the 
plasma markers of the intertwined dynamic processes of coagulation and fibrinolysis are part 
of a highly reactive and dynamic defense mechanism to protect the integrity of the 
vasculature, and they generally have short half-lives 529. Thus, the acute phase before, during, 
and immediately after the onset of symptoms is not easily caught in a clinical study, and the 
risk of confounding elements accumulates when a single postictal assessment is to reflect the 
dynamic situation just before the acute stage as well as the time after the onset of symptoms. 
The time range since symptoms was from a few days to over 200 days in the ipsilaterally 
symptomatic, median at 41 days, and even longer in otherwise symptomatic patients; 
accordingly, the acute-phase reaction cannot be expected to be shown, and the subsequent 
phases such as endothelial regeneration could also induce variance. Thirdly, atherosclerosis is 
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a systemic process, as previously discussed, and drastic conclusions on a local process on the 
basis of blood samples may be misleading. Fourthly, a considerable number of patients were 
on warfarin, which has a confounding effect on part of the results. In addition, 
haemorheological conclusions are made indirectly on the basis of basic parameters without 
direct rheological measurements.  
 
 
6.6  Summary of findings and their implications 
 
The studies (II-III)  yielded findings indicating that a high-grade CS may have implicit effects 
on the brain and its functions. Another main finding was that the haemodynamic aspect (I) 
and the microcirculation (IV) may influence the evolution of symptoms in these patients.   
 
The main results in the brain diffusion and perfusion studies (I-II) were the ipsilateral findings 
of enhanced diffusion and the lower perfusion in the WM, as well as the corrective effect of 
CEA on them. Unlike the partially reversible diffusional elevation, the perfusion impairment 
differed between asymptomatic and symptomatic patients. The haemodynamic effect was 
reflected by the TCD modality as well. Both diffusion and perfusion results support the 
etiology of a chronic low-grade ischaemia, which has been the central hypothetical etiology to 
WM lesions 14.The preoperatively elevated ADCav values were a novel finding suggesting an 
association between WM degeneration and CS. The perfusion data (II) are in line with 
previous studies on haemodynamics in carotid stenosis or occlusion, but they underscore the 
haemodynamic aspect in the symptomatic disease 77, 343, 502. The results serve as a reminder 
not to overlook the haemodynamic state, either, which may have a contributory or synergistic 
role along with the unstable plaque seeding emboli 347, 351. A closer haemodynamic evaluation 
could also help in selecting asymptomatic patients with CS for operative treatment.  
    
The cognitive performance of patients with a high-grade CS (III) was found to be poorer than 
in healthy peers, on the basis of a multimodal approach and a versatile neuropsychological 
battery, in line with previous reports 416-418, 530. The degree of impairment correlated with the 
severity of WM degeneration 531, 532. However, the patients’ postoperative cognitive 
improvement was equally good as that of controls in repeated testing, and even better in some 
domains in patients who initially had a deeper hypoperfusion, primarily in executive 
functions. The association of CEA and cognition appears twofold: despite a risk of transient 
cognitive decline, surgery of a high-grade CS in a dedicated unit seems to be a fairly safe 
means to protect the brain, and there is even a possibility of cognitive benefit in subgroups. 
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Prospective identification of individuals with the optimum benefit warrants further study with 
larger samples and multimodal designs, longer follow-up, and evaluation of the true impact of 
the observed cognitive dysfunction on the subjects’ daily life and its quality.  Much more data 
is needed also on the association of ADC levels and the progress of WM changes before the 
role of CEA as a potential means of WM protection can be established, and application of 
diffusion tensor imaging, possibly combined with other imaging modalities, would be more 
informative than the mere ADC approach.  
 
Both fibrinolytic mechanisms and haemorheology  may be associated with the evolution of 
CS into the symptomatic stage (IV). Elevated levels of tPA antigen may be an indicator of 
carotid plaque instability and associated thrombogenic potential, and higher viscosity of 
blood, an established risk factor for stroke, may contribute to symptoms in severe CS. A 
longitudinal follow-up study of the mediators, a more comprehensive overview of the 
haemostatic process, direct measurements of viscosity, and a more specific look at the flow 
conditions, in a closer temporal proximity to the acute stage, would probably provide more 
accurate information on the interplay of coagulation, fibrinolysis, and haemorheology.  
 
On the basis of these results, future carotid trials could be encouraged to take advantage of 
more functional and dynamic methods for an improved evaluation and risk assessment in 
carotid disease, instead of the mere categorical observation of stenosis degree. With the 
evolution of angioplasty and stenting, the cognitive aspect and multimodality should be 
incorporated into the design of carotid trials, particularly as the recent systematic reviews 
have concluded that a greater number of brain lesions are detected after carotid stenting than 
after CEA 463, 476. Apart from this difference with potential cognitive sequelae, the putative 
effects of altered perfusion and diffusion would probably be analogical after stenting and 
CEA, but remain to be verified by further study.  
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7.  CONCLUSIONS   
         
1.   Cerebral haemodynamics in symptomatic patients with a high-grade carotid stenosis is 
less well adapted and more often results in haemodynamic deficit than in asymptomatic 
patients. Accordingly, the haemodynamics of symptomatic patients benefit more from 
removal of stenosis as indicated by improvement in perfusion, pulsatility, and reactivity.  
 
2.   A high-grade CS is associated with elevated ADCav values in the WM and watershed 
regions of the ipsilateral hemisphere in comparison to the contralateral hemisphere and to 
healthy control population. The interhemispheric difference is promptly abolished by CEA, 
but the ADCav  levels remain higher than in healthy controls also in the chronic stage. This 
implies the existence of both reversible and irreversible component in the effect a high-grade 
CS has on the WM, and it may indicate an association to the WM degeneration. 
 
3.  Carotid occlusive disease is associated with a lower level of cognitive functioning 
irrespective of vascular events. After carotid surgery, despite a trend towards transient 
cognitive decline, the patients improve within months as expected by learning effect in 
repeated testing. Cognitive improvement is greater in patients with deeper preoperative 
cerebral hypoperfusion, and the improvement is most evident in the domain of executive 
functions. 
 
4.   Symptomatic patients with a high-grade stenosis differ in terms of coagulation activity 
and fibrinolysis, as well as basic haemorheology. Mediators of fibrinolysis and unfavourable 
haemorheology may contribute to progress of an asymptomatic carotid disease into a 
symptomatic one in patients with a high-grade CS. 
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